[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 245
1. Jim MA, Perdue DG, Richardson LC, Espey DK, Redd JT, Martin HJ, Kwong SL, Kelly JJ, Henderson JA, Ahmed F: Primary liver cancer incidence among American Indians and Alaska Natives, US, 1999-2004. Cancer; 2008 Sep 1;113(5 Suppl):1244-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary liver cancer incidence among American Indians and Alaska Natives, US, 1999-2004.
  • BACKGROUND: American Indians and Alaska Natives (AI/AN) experience higher morbidity and mortality from primary liver cancer than other United States (US) populations, but racial misclassification in medical records results in underestimates of disease burden.
  • METHODS: To reduce misclassification, National Program of Cancer Registries and Surveillance, Epidemiology, and End Results data were linked with Indian Health Service (IHS) enrollment records to compare primary liver cancer incidence and stage at diagnosis between AI/AN and non-Hispanic whites (NHW) living within the regionalized IHS Contract Health Service Delivery Area counties.
  • Liver cancer incidence rates among AI/AN males and females were higher than those among NHW males and females for all regions except for the East.
  • CONCLUSIONS: Reducing racial misclassification revealed higher disparities in primary liver cancer incidence between NHW and AI/AN populations than previously reported.
  • Further description of the reasons for regional differences in this disparity is needed, as are programs to reduce risk factors and to diagnose primary liver cancer at earlier, more treatable stages.

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Native American Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18720380.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA089139; United States / NCCDPHP CDC HHS / DP / U50 DP424071-04
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


2. Zhang CY, Huang TR, Yu JH, Zhang ZQ, Li JL, Deng W, Ye SY, Zhou DN, He ZF: Epidemiological analysis of primary liver cancer in the early 21st century in Guangxi province of China. Chin J Cancer; 2010 May;29(5):545-50
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiological analysis of primary liver cancer in the early 21st century in Guangxi province of China.
  • BACKGROUND AND OBJECTIVE: In Guangxi province, from 1970s to 1990s, the mortality of primary liver cancer (PLC) ranked the first among a variety of malignant tumors.
  • METHODS: Multi stage stratified cluster random sampling method was used to select 9 counties (cities or urban areas) as sample points.
  • [MeSH-major] Liver Neoplasms / epidemiology. Liver Neoplasms / mortality. Mortality / trends
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Child. Child, Preschool. China / epidemiology. Female. Humans. Infant. Male. Middle Aged. Sex Distribution. Young Adult

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20426906.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


3. Sun HW, Chen LH, Wei CJ, Zheng XK, Li QS, Guan J: [Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for massive primary liver cancer]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Jun;29(6):1133-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for massive primary liver cancer].
  • OBJECTIVE: To evaluate the outcomes of patients with unresectable massive primary liver cancer (PLC) receiving three-dimensional conformal radiotherapy (3-DCRT) combined with transcatheter arterial chemoembolization (TACE).
  • METHODS: From January 2001 to December 2004, 84 patients with unresectable massive PLC (tumor size> or =10 cm) received 3-DCRT combined with TACE, including 49 cases in UICC/AJCC T(3) stage and 35 cases in T(4) stages.
  • Child-Pugh grade A of liver cirrhosis was present in 64 cases and grade B in 20 cases.
  • T stage, GTV, PVTT and fraction size had no significant impact on the overall survival.
  • [MeSH-major] Chemoembolization, Therapeutic / methods. Liver Neoplasms / therapy. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adult. Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Carcinoma, Hepatocellular / therapy. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Imaging, Three-Dimensional / methods. Male. Middle Aged. Mitomycin / administration & dosage. Radiotherapy Dosage. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19726341.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / hydroxycamptothecinum; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


Advertisement
4. Aslam MI, Kelkar A, Sharpe D, Jameson JS: Ten years experience of managing the primary tumours in patients with stage IV colorectal cancers. Int J Surg; 2010;8(4):305-13
Genetic Alliance. consumer health - TEN.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ten years experience of managing the primary tumours in patients with stage IV colorectal cancers.
  • INTRODUCTION: Approximately 20% of patients with colorectal cancer have metastases at the time of presentation.
  • Such patients are often offered systemic chemotherapy but debate continues as to whether these patients benefit from resection of the primary tumour.
  • We describe our ten years experience of managing the primary tumours in patients with stage IV colorectal cancer.
  • PATIENTS & METHODS: 920 consecutive patients presenting with stage IV colorectal cancer disease were identified from the Leicester Colorectal Cancer database.
  • Patients undergoing resection of the primary tumour (Resection Group) with the residual metastatic disease were compared to those patients who had not their primary tumour excised (Non-Resection Group).
  • The multivariate analysis of different survival predicting variables, revealed the resection of the primary tumour as an independent predictor of overall survival (p < 0.001).
  • The univariate analysis of resection group identified age at presentation, tumour site, tumour stage (pT), lymph nodal stage (pN), complete histological resection, tumour fixity, ASA grade, mode of surgery, post-operative chemotherapy and sites of metastasis as significant factors (p < 0.05) for survival prediction.
  • Treatment with post-operative chemotherapy and a smaller volume of liver metastases were associated with prolonged survival (p < 0.05).
  • CONCLUSIONS: Surgical resection of primary tumour for stage IV colorectal cancers is associated with prolonged survival for selected patients.
  • Age at presentation, extent of liver involvement, tumour fixity and ASA grade can help to decide the patients who will benefit from surgery.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Factors. Survival Analysis. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Surgical Associates Ltd. All rights reserved.
  • (PMID = 20380899.001).
  • [ISSN] 1743-9159
  • [Journal-full-title] International journal of surgery (London, England)
  • [ISO-abbreviation] Int J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


5. Konyalian VR, Rosing DK, Haukoos JS, Dixon MR, Sinow R, Bhaheetharan S, Stamos MJ, Kumar RR: The role of primary tumour resection in patients with stage IV colorectal cancer. Colorectal Dis; 2007 Jun;9(5):430-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of primary tumour resection in patients with stage IV colorectal cancer.
  • OBJECTIVE: The management of stage IV colorectal cancer is controversial.
  • Resection of the primary tumour to prevent obstruction, bleeding or perforation is the traditional approach, although survival benefit is undetermined.
  • The purpose of this study was to determine the role of resection of the primary tumour in patients with stage IV colorectal cancer, with specific attention paid to survival benefit and safety.
  • METHOD: This was a retrospective review of all stage IV colon and rectal cancer patients in our tumour registry between 1991 and 2002.
  • Survival analysis was performed to assess the effect of primary tumour resection on long-term survival.
  • Sixty-two (57%) patients (group I) underwent resection of the primary tumour, whereas 47 (43%) patients (group II) were managed without resection.
  • After controlling for age, sex, tumour location and level of liver involvement as well as liver function, patients who underwent resection still survived longer (HR = 0.34, 95% CI: 0.21-0.55).
  • CONCLUSION: Palliative resection of the primary tumour plays an essential role in the management of stage IV colorectal cancer.
  • Limited metastatic tumour burden of the liver was associated with better survival in such patients.
  • [MeSH-major] Colectomy / adverse effects. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cohort Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Palliative Care. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17504340.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


6. Gervasini G, García-Martín E, Ladero JM, Pizarro R, Sastre J, Martínez C, García M, Diaz-Rubio M, Agúndez JA: Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients. BMC Cancer; 2007;7:118
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients.
  • The role of gene polymorphisms of several cytochrome P450 enzymes in digestive cancer risk has been extensively investigated.
  • This study aims to examine associations between common CYP3A4 and CYP3A5 polymorphisms and digestive cancer risk.
  • METHODS: CYP3A4 and CYP3A5 genotypes were determined in 574 individuals including 178 patients with primary liver cancer, 82 patients with gastric cancer, 151 patients with colorectal cancer, and 163 healthy individuals.
  • RESULTS: The variant allele frequencies for patients with liver cancer, gastric cancer, colorectal cancer and healthy controls, respectively, were: CYP3A4*1B, 4.8 % (95% C.I.
  • No differences in genotypes, allele frequencies, or association between variant alleles were observed with regard to gender, age at diagnosis, tumour site or stage.
  • [MeSH-major] Colorectal Neoplasms / genetics. Cytochrome P-450 Enzyme System / genetics. Genetic Variation. Liver Neoplasms / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Chi-Square Distribution. Cytochrome P-450 CYP3A. Female. Gene Expression Regulation, Neoplastic. Genetic Predisposition to Disease. Genotype. Humans. Male. Middle Aged. Polymorphism, Genetic. Reference Values. Sensitivity and Specificity. Survival Analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 2000 Jan-Feb;20(1B):519-22 [10769717.001]
  • [Cites] Am J Epidemiol. 2004 Nov 1;160(9):825-41 [15496535.001]
  • [Cites] Carcinogenesis. 2001 Feb;22(2):209-14 [11181440.001]
  • [Cites] Clin Chem. 2001 Feb;47(2):348-51 [11159790.001]
  • [Cites] J Gastroenterol Hepatol. 2001 Jun;16(6):631-5 [11422615.001]
  • [Cites] Carcinogenesis. 2001 Aug;22(8):1323-6 [11470765.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Dec;10(12):1259-66 [11751443.001]
  • [Cites] Pharmacogenetics. 2002 Mar;12(2):145-50 [11875368.001]
  • [Cites] Clin Pharmacol Ther. 2002 Mar;71(3):196-204 [11907494.001]
  • [Cites] Teratog Carcinog Mutagen. 2002;22(5):385-92 [12210502.001]
  • [Cites] Drug Metab Rev. 2002 Aug;34(3):667-76 [12214673.001]
  • [Cites] Br J Cancer. 2002 Sep 9;87(6):681-6 [12237780.001]
  • [Cites] Clin Chem. 2002 Oct;48(10):1668-71 [12324482.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1019-24 [12376502.001]
  • [Cites] Carcinogenesis. 2002 Nov;23(11):1839-49 [12419832.001]
  • [Cites] Carcinogenesis. 2002 Nov;23(11):1897-901 [12419838.001]
  • [Cites] Hum Hered. 2002;54(1):13-21 [12446983.001]
  • [Cites] Toxicology. 2002 Dec 27;181-182:447-52 [12505350.001]
  • [Cites] Br J Clin Pharmacol. 2003 Jan;55(1):68-76 [12534642.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2003;43:149-73 [12171978.001]
  • [Cites] J Pharm Pharmacol. 2003 Jan;55(1):59-66 [12625868.001]
  • [Cites] Mol Cancer Ther. 2003 Jun;2(6):527-34 [12813131.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Sep;12(9):928-32 [14504207.001]
  • [Cites] Pharmacogenetics. 2003 Oct;13(10):595-606 [14515058.001]
  • [Cites] Pharmacogenetics. 2003 Oct;13(10):607-18 [14515059.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Nov;18(11):1257-63 [14535982.001]
  • [Cites] Pharmacogenomics. 2004 Apr;5(3):243-72 [15102541.001]
  • [Cites] Curr Drug Metab. 2004 Jun;5(3):211-24 [15180491.001]
  • [Cites] Clin Pharmacol Ther. 2004 Aug;76(2):99-103 [15289786.001]
  • [Cites] Am J Epidemiol. 2004 Nov 1;160(9):842-52 [15496536.001]
  • [Cites] Hum Genet. 1986 Aug;73(4):320-6 [3017841.001]
  • [Cites] Carcinogenesis. 1991 Feb;12(2):355-9 [1899812.001]
  • [Cites] Cancer Res. 1994 Jan 1;54(1):101-8 [8261428.001]
  • [Cites] J Pharmacol Exp Ther. 1994 Jul;270(1):414-23 [8035341.001]
  • [Cites] Carcinogenesis. 1994 Dec;15(12):2715-20 [8001226.001]
  • [Cites] Pharmacogenetics. 1994 Oct;4(5):247-59 [7894497.001]
  • [Cites] Carcinogenesis. 1995 Sep;16(9):2167-70 [7554070.001]
  • [Cites] Age Ageing. 1997 Mar;26(2):147-51 [9177672.001]
  • [Cites] Mutat Res. 1997 May 12;376(1-2):153-60 [9202751.001]
  • [Cites] Carcinogenesis. 1997 Aug;18(8):1623-30 [9276639.001]
  • [Cites] J Natl Cancer Inst. 1998 Aug 19;90(16):1225-9 [9719084.001]
  • [Cites] Environ Health Perspect. 1994 Oct;102(10):852-3 [9644192.001]
  • [Cites] Cancer Res. 2004 Nov 15;64(22):8461-7 [15548719.001]
  • [Cites] World J Gastroenterol. 2005 Jan 21;11(3):331-5 [15637738.001]
  • [Cites] J Cell Biochem. 2005 Apr 1;94(5):917-43 [15578590.001]
  • [Cites] World J Gastroenterol. 2005 Mar 28;11(12):1867-71 [15793883.001]
  • [Cites] Cancer Causes Control. 2004 Dec;15(10):1077-83 [15801491.001]
  • [Cites] Cancer Lett. 2005 Jul 28;225(2):275-82 [15978331.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5552-9 [16110016.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Dec 9;338(1):299-305 [16171783.001]
  • [Cites] BMC Clin Pharmacol. 2005;5:4 [16253141.001]
  • [Cites] Int J Cancer. 2004 Nov 1;112(2):259-64 [15352038.001]
  • [Cites] Scand J Gastroenterol. 2000 Oct;35(10):1087-91 [11099063.001]
  • (PMID = 17605821.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.13.67 / CYP3A4 protein, human; EC 1.14.14.1 / CYP3A5 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP3A
  • [Other-IDs] NLM/ PMC1931602
  •  go-up   go-down


7. Babiera GV, Rao R, Feng L, Meric-Bernstam F, Kuerer HM, Singletary SE, Hunt KK, Ross MI, Gwyn KM, Feig BW, Ames FC, Hortobagyi GN: Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol; 2006 Jun;13(6):776-82
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor.
  • BACKGROUND: Currently, therapy for breast cancer patients with stage IV disease and an intact primary tumor is metastasis directed; the primary tumor is treated only when it causes symptoms.
  • METHODS: We reviewed the records of all breast cancer patients treated at our institution between 1997 and 2002 who presented with stage IV disease and an intact primary tumor.
  • RESULTS: Of 224 patients identified, 82 (37%) underwent surgical extirpation of the primary tumor (segmental mastectomy in 39 [48%] and mastectomy in 43 [52%]), and 142 (63%) were treated without surgery.
  • CONCLUSIONS: Removal of the intact primary tumor for breast cancer patients with synchronous stage IV disease is associated with improvement in metastatic progression-free survival.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Neoplasms / secondary. Bone Neoplasms / surgery. Combined Modality Therapy. Disease Progression. Female. Humans. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2006 Jun;13(6):759-60 [16604472.001]
  • [CommentIn] Ann Surg Oncol. 2007 Apr;14(4):1519-20 [17225978.001]
  • (PMID = 16614878.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


8. Sloane D, Chen H, Howell C: Racial disparity in primary hepatocellular carcinoma: tumor stage at presentation, surgical treatment and survival. J Natl Med Assoc; 2006 Dec;98(12):1934-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Racial disparity in primary hepatocellular carcinoma: tumor stage at presentation, surgical treatment and survival.
  • OBJECTIVES: The incidence and mortality rates from primary hepatocellular carcinoma (HCC) are higher in black Americans compared to whites.
  • The goal of this study was to determine if there are racial disparities in HCC stage at diagnosis and treatment.
  • METHODS: We compared patient age, tumor stage, rates of surgical intervention and survival in black (n=1718) and white (n=9752) HCC cases between 1992 and 2001 in the Surveillance, Epidemiology and End Results (SEER)-11 + Alaska database.
  • CONCLUSIONS: Black HCC patients have more advanced tumor stage at diagnosis and lower rates of both surgical intervention and survival.

  • MedlinePlus Health Information. consumer health - African American Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2002 Mar 6;94(5):334-57 [11880473.001]
  • [Cites] Am J Gastroenterol. 2003 Sep;98(9):2060-3 [14499788.001]
  • [Cites] Ann Intern Med. 2003 Nov 18;139(10):817-23 [14623619.001]
  • [Cites] CA Cancer J Clin. 2004 Mar-Apr;54(2):78-93 [15061598.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Mar;4(3):355-60 [16527700.001]
  • [Cites] Cancer Causes Control. 2004 Aug;15(6):601-9 [15280639.001]
  • [Cites] Cancer Pract. 1998 May-Jun;6(3):182-7 [9652250.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):413-8 [16365180.001]
  • [Cites] Liver Transpl. 2004 Jul;10(7):834-41 [15237365.001]
  • (PMID = 17225837.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / 1 K24 DK072036-01
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2569668
  •  go-up   go-down


9. Karoui M, Soprani A, Charachon A, Delbaldo C, Vigano L, Luciani A, Cherqui D: Primary chemotherapy with or without colonic stent for management of irresectable stage IV colorectal cancer. Eur J Surg Oncol; 2010 Jan;36(1):58-64
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary chemotherapy with or without colonic stent for management of irresectable stage IV colorectal cancer.
  • AIM: Management of patients with irresectable stage IV colorectal cancer is controversial.
  • Since 2000, we have favoured primary chemotherapy with stent insertion in case of obstructive tumor.
  • PATIENTS AND METHODS: From 2000 to 2007, 68 of 115 consecutive patients admitted with stage IV colorectal cancer were considered irresectable.
  • RESULTS: Of 68 patients, 37 received the intended primary chemotherapy, with stent insertion in 19, 13 required surgery as initial management and 18 patients received supportive care only.
  • Twelve patients in the primary chemotherapy group developed local complication, including bowel obstruction in 9, successfully managed by stent in 6 of them.
  • Median survival was 6.7 and 15.4 months for the whole series and patients treated by primary chemotherapy, respectively (p<0.0001).
  • On multivariate analysis, age, CEA level, primary chemotherapy and secondary curative resection were independently associated with survival.
  • CONCLUSION: In unselected patients with irresectable stage IV colorectal cancer, primary chemotherapy with or without stent is feasible in more than 50% of cases and is associated with a low rate of secondary surgery for complicated primary tumor.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colectomy. Female. Humans. Intestinal Obstruction / etiology. Intestinal Obstruction / therapy. Liver Neoplasms / secondary. Male. Middle Aged. Palliative Care. Survival Analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19926243.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Shen XY, Chai CH, Xiao WB, Wang QD: Diagnostic value of the fluoroscopic triggering 3D LAVA technique for primary liver cancer. Hepatobiliary Pancreat Dis Int; 2010 Apr;9(2):159-63
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of the fluoroscopic triggering 3D LAVA technique for primary liver cancer.
  • BACKGROUND: Primary liver cancer (PLC) is one of the common malignant tumors.
  • Liver acquisition with acceleration volume acquisition (LAVA), which allows simultaneous dynamic enhancement of the hepatic parenchyma and vasculature imaging, is of great help in the diagnosis of PLC.
  • This study aimed to evaluate application of the fluoroscopic triggering 3D LAVA technique in the imaging of PLC and liver vasculature.
  • RESULTS: Thirty-eight patients gave high quality images of 72 nodules in the liver for diagnosis.
  • Furthermore, small early-stage enhancing hepatic lesions and the parallel portal vein were also well displayed.
  • [MeSH-major] Fluoroscopy / methods. Imaging, Three-Dimensional / methods. Liver / pathology. Liver Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Female. Hepatic Artery / pathology. Humans. Male. Middle Aged. Portal Vein / pathology

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20382587.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


11. Gervaz P, Rubbia-Brandt L, Andres A, Majno P, Roth A, Morel P, Mentha G: Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes. Ann Surg Oncol; 2010 Oct;17(10):2714-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes.
  • BACKGROUND: We report the histopathological results of a novel "inversed" strategy designed to manage patients with colorectal cancer (CRC) who have synchronous liver metastases by using chemotherapy first, liver surgery second, and resection of the primary tumor as a final step.
  • This study was designed to compare the response to chemotherapy in liver metastases, primary tumors, and locoregional lymph nodes.
  • METHODS: Twenty-nine patients with stage IV CRC received a combination of oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin (OCFL) for 3-4 months.
  • Primary tumor location was right colon (n = 5), left colon (n = 7), and rectum (n = 17 patients).
  • TRG scores correlated across disease sites (Spearman correlation coefficients for TRG in the primary tumor and lymph nodes was 0.59 [P = 0.005]; for the primary tumor and metastases 0.44 [P = 0.021]; and for lymph nodes and metastases 0.58 [P = 0.006]).
  • Complete absence or poor tumor response (TRG4/5) was significantly more frequent in primary tumors (35.7%) and locoregional lymph nodes (38%) than in liver metastases (6.9%; McNemar test, P = 0.02).
  • CONCLUSIONS: In patients with stage IV colorectal cancer, liver metastases exhibit a better histological response than primary tumors to OCFL neoadjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Lymph Nodes / drug effects. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Prospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20405223.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


12. Liang SX, Jiang GL, Zhu XD, Fu XL, Li FX, Huang QF, Wang AY, Chen L, Lu HJ: [Prognostic factor of primary liver cancer treated by hypofractionated three-dimensional conformal radiotherapy]. Zhonghua Zhong Liu Za Zhi; 2005 Oct;27(10):613-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factor of primary liver cancer treated by hypofractionated three-dimensional conformal radiotherapy].
  • OBJECTIVE: To evaluate the toxicity and efficacy of primary liver cancer (PLC) treated by hypofractionated three-dimensional conformal radiotherapy (3DCRT) and investigate the prognostic factors.
  • 108 patients had Child-Pugh Grade A liver cirrhosis and 20 Child-Pugh Grade B liver cirrhosis.
  • T stage (P = 0.001), GTV (P = 0.0001), PVTT (P = 0.0001) and Child-Pugh Grade (P = 0.0001) had significant impact on the overall survival.
  • CONCLUSION: T stage, GTV, PVTT and Child-Pugh Grade have significant impact on the overall survival in primary liver cancer patients treated by three-dimensional conformal radiotherapy.
  • [MeSH-major] Carcinoma, Hepatocellular / radiotherapy. Liver Neoplasms / radiotherapy. Radiotherapy Planning, Computer-Assisted. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Imaging, Three-Dimensional. Male. Middle Aged. Prognosis. Regression Analysis. Retrospective Studies

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16438872.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


13. Chun YS, Vauthey JN, Ribero D, Donadon M, Mullen JT, Eng C, Madoff DC, Chang DZ, Ho L, Kopetz S, Wei SH, Curley SA, Abdalla EK: Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival. J Gastrointest Surg; 2007 Nov;11(11):1498-504; discussion 1504-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival.
  • BACKGROUND: Two-stage hepatectomy has been proposed for patients with bilateral colorectal liver metastases (CLM).
  • The aim of this study was to compare the outcome of patients with CLM treated with preoperative chemotherapy followed by one- or two-stage hepatectomy.
  • METHODS: From a prospective database, 214 consecutive patients who received preoperative systemic chemotherapy (fluoropyrimidine with irinotecan or oxaliplatin) followed by planned one- or two-stage hepatectomy were retrospectively analyzed (1998-2006).
  • In patients undergoing two-stage procedures, minor hepatectomy (wedge or segmental resection[s]) was systematically performed before major (more than three segments), second-stage hepatectomy.
  • RESULTS: One- (group I) and two-stage (group II) hepatectomies were performed in 184 and 21 patients, respectively.
  • For group I, group II first stage, and group II second stage, respectively, morbidity (24%, 24%, 43%), median hospital stay (7 days, 6 days, 6.5 days) and 30 days postoperative mortality (2%, 0%, 0%) were not significantly different (P = NS).
  • CONCLUSIONS: Two-stage hepatectomy with preoperative chemotherapy results in comparable morbidity and survival rates as one-stage hepatectomy.
  • [MeSH-major] Hepatectomy / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colorectal Neoplasms / pathology. Disease-Free Survival. Female. Humans. Length of Stay. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasms, Multiple Primary / surgery. Risk Assessment

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17849166.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Saikawa Y, Kubota T, Takahashi T, Akatsu Y, Nakamura R, Yoshida M, Shigematsu N, Otani Y, Kumai K, Hibi T, Kitajima M: Is chemoradiation effective or harmful for stage VI gastric cancer patients? Oncol Rep; 2005 May;13(5):865-70
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is chemoradiation effective or harmful for stage VI gastric cancer patients?
  • We aim to clarify beneficial effect of pre-operative radiation with chemotherapy in highly advanced gastric cancer patients, evaluating histological response, toxicity and patients' quality of life (QOL).
  • We used pre-operative radiation with S-1 and low-dose cisplatin to treat 8 patients with highly advanced gastric cancer (clinical stage IV) in a pilot study.
  • Clinical staging after therapy showed 5 PRs (partial response), 2 NCs (no change), and 1 PD (partial disease) following evaluation of the primary tumor and suspicious metastatic lesions in the lymph nodes, esophagus, liver, and peritoneum, for a response rate of 62.5% (5/8 cases).
  • The survival analysis showed that 5 out of the 8 patients died within 10 months after initiating therapy, while 3 patients are alive without recurrence at 15, 18, and 30 months after therapy, suggesting a relatively good outcome for clinical stage IV gastric cancer.
  • Chemoradiation may be a powerful regimen for obtaining histological response with tolerable toxicity and improved QOL in highly advanced gastric cancer patients.
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymphatic Metastasis. Male. Neoplasm Staging. Quality of Life. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15809751.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


15. Burcoveanu C, Stefan S, Ursache A, Pricop A: [Primary and secondary hepatic cancer--specifics of surgical treatment in correlation with disease stage]. Rev Med Chir Soc Med Nat Iasi; 2009 Oct-Dec;113(4):1131-5
Hazardous Substances Data Bank. ETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary and secondary hepatic cancer--specifics of surgical treatment in correlation with disease stage].
  • Given the necessity of increasing their resectability, there are evaluated the possibilities of surgical treatment for these types of hepatic cancer, in the context of dominant clinical presence of advanced hepatic tumors.
  • MATERIAL AND METHOD: The study comprises 190 patients during 01.01.2000-31.12.2007, in the IIIrd Surgical Clinic, Iaşi, with primary and secondary hepatic tumors.
  • [MeSH-major] Anti-Infective Agents, Local / administration & dosage. Catheter Ablation. Ethanol / administration & dosage. Hepatectomy / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20191887.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Anti-Infective Agents, Local; 3K9958V90M / Ethanol
  •  go-up   go-down


16. Law WL, Chu KW: Outcomes of resection of stage IV rectal cancer with mesorectal excision. J Surg Oncol; 2006 Jun 1;93(7):523-8
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of resection of stage IV rectal cancer with mesorectal excision.
  • BACKGROUND: There is no consensus as to the management of the primary rectal cancer in the presence of distant metastasis and data on the outcomes of radical resection in stage IV rectal cancer are limited.
  • This study aims to evaluate the results of resection of rectal cancer in the patients with stage IV disease and to analyze the factors that might affect the survival of these patients.
  • METHODS: Of the 744 patients with radical resection of primary rectal and rectosigmoid cancer during the study period from August 1993 to July 2002, 70 had stage IV disease on the initial presentation.
  • The median cancer-specific survival of the patients who survived the surgery was 15.2 months.
  • Multivariate analysis showed that the presence of gross residual local disease, lymph node metastasis, liver involvement of over 50%, the absence of surgical management of liver metastasis and those without chemotherapy were independent factors associated with poor survival.
  • CONCLUSIONS: Postoperative mortality and morbidity were acceptable in patients with stage IV rectal cancer.
  • However, in patients with extensive liver involvement and advanced local disease, resection is not worthwhile because of the poor survival.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Peritoneal Neoplasms / secondary. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16705728.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Zivanovic O, Eisenhauer EL, Zhou Q, Iasonos A, Sabbatini P, Sonoda Y, Abu-Rustum NR, Barakat RR, Chi DS: The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol; 2008 Feb;108(2):287-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer.
  • OBJECTIVE: To analyze the impact of bulky upper abdominal disease (UAD) cephalad to the greater omentum on surgical outcomes for patients with stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal carcinoma.
  • METHODS: All patients with stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal carcinoma who underwent primary cytoreductive surgery at our institution from 1989 to 2005 were eligible for the study.
  • UAD cephalad to the greater omentum was defined as cancerous lesions involving the diaphragm, liver, porta hepatis, spleen, pancreas, stomach, and lesser sac.
  • CONCLUSION: The upper abdomen cephalad to the greater omentum is frequently involved in patients with stage IIIC ovarian, tubal, and peritoneal carcinoma.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Staging


18. Segaert I, Mottaghy F, Ceyssens S, De Wever W, Stroobants S, Van Ongeval C, Van Limbergen E, Wildiers H, Paridaens R, Vergote I, Christiaens MR, Neven P: Additional value of PET-CT in staging of clinical stage IIB and III breast cancer. Breast J; 2010 Nov-Dec;16(6):617-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Additional value of PET-CT in staging of clinical stage IIB and III breast cancer.
  • To evaluate retrospectively the accuracy of integrated PET/CT, against PET, CT, or conventional staging in breast cancer.
  • Seventy consecutive biopsy proven clinical stage IIB and III breast cancer patients were included.
  • Descriptive statistics of integrated PET/CT for the primary tumor, nodal status and metastasis detection were compared to PET, CT with contrast, and conventional staging (biochemistry, chest X-ray, liver ultrasound, and bone scintigraphy).
  • Sensitivity of PET/CT for primary tumor and nodal status was 97.1% and 62.5%, respectively.
  • PET/CT is able to visualize most clinical stage IIB and III primary breast cancers.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Retrospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Wiley Periodicals, Inc.
  • (PMID = 21070439.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Sun FR, Meng YM, Wang BY, Liu YF, Liu CX, Xie DW, Ding YY, Li JP, Ma L: [Correlations between MELD score and left ventricular function in patients with end-stage liver disease]. Zhonghua Gan Zang Bing Za Zhi; 2010 Oct;18(10):758-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlations between MELD score and left ventricular function in patients with end-stage liver disease].
  • OBJECTIVE: To evaluate the correlations between MELD score and left ventricular function in patients with end-stage liver disease.
  • METHODS: A total of 92 patients who prepared for orthotopic liver transplantation from January 2002 to May 2008 were enrolled in this study.
  • Of these Patients, 75 were males and 17 were females, and the mean age was 50.3+/-9.5 years; 85 were cirrhosis, 7 were cirrhosis with primary liver cancer.
  • According to MELD (the Model for End-stage Liver Disease) scoring system, these subjects were categorized into three groups: MELD score is less than or equal to 9 points (31 cases, 33.7%); 10 is less than or equal to MELD score is less than or equal to 19 points (45 cases, 48.9%); MELD score is more than or equal to 20 points (16 cases, 17.4%).
  • CONCLUSIONS: There are different degrees of left ventricular structure, function and electrophysiological changes in patients with end-stage liver disease, these anomalies also will be increased with the MELD score increasing.
  • [MeSH-major] End Stage Liver Disease / physiopathology. Liver Cirrhosis / physiopathology. Ventricular Function, Left
  • [MeSH-minor] Adult. Female. Humans. Liver Failure / physiopathology. Liver Failure / surgery. Liver Neoplasms / physiopathology. Liver Neoplasms / surgery. Liver Transplantation. Male. Middle Aged

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21059293.001).
  • [ISSN] 1007-3418
  • [Journal-full-title] Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  • [ISO-abbreviation] Zhonghua Gan Zang Bing Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


20. Margery J, Milleron B, Vaylet F, Grahek D, Lebeau B, Mangiapan G, Bonardel G, de Labriolle-Vaylet C, Meignan M, Carette MF, Talbot JN, Housset B: [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study]. Rev Pneumol Clin; 2010 Oct;66(5):313-20
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study].
  • [Transliterated title] Impact de la tomographie par émission de positons au 18-FDG dans la prise en charge des patients porteurs d'un cancer bronchique non à petites cellules a priori opérable. Etude prospective multicentrique française.
  • BACKGROUND: Whole-body (18)F-deoxyglucose positron emission tomography (FDG-PET) has the potential to improve the management of non-small-cell lung cancer (NSCLC).
  • The stage was lowered in eight cases (9%) and raised in 18 cases (20.2%).
  • These modifications were retrospectively justified in 9/19 cases, and consisted of 2/4 modifications of the surgical procedure (one hilar and one adrenal metastasis not confirmed histologically), 4/12 further investigations (axillary and liver biopsies, mediastinoscopy, occult colon cancer) and three indications for palliative treatment, in patients who all died within 3 months after FDG-PET.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colonic Neoplasms / radionuclide imaging. Decision Making. False Positive Reactions. Female. Humans. Liver Neoplasms / secondary. Lymph Node Excision. Lymphatic Metastasis / radionuclide imaging. Male. Mediastinoscopy. Middle Aged. Neoplasm Staging. Neoplasms, Unknown Primary / radionuclide imaging. Palliative Care. Patient Care Planning. Pneumonectomy. Prospective Studies. Retrospective Studies. Tomography, X-Ray Computed. Whole Body Imaging

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 21087727.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


21. Shah I, Sefvan O, Luqman U, Ibrahim W, Mehmood S, Alamgir W: Clinical stage of oral cancer patients at the time of initial diagnosis. J Ayub Med Coll Abbottabad; 2010 Jul-Sep;22(3):61-3
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical stage of oral cancer patients at the time of initial diagnosis.
  • BACKGROUND: Squamous cell carcinoma is the most common oral cancer.
  • Late diagnosis is however common around the world and contributes to the high morbidity and mortality related to oral cancer.
  • The objective of this study was to determine the clinical stage of oral cancer patients at the time of diagnosis.
  • METHODS: This retrospective study was carried out on 334 oral cancer patients who presented to the outdoor departments of Armed Forces Institute of Dentistry, and Armed Forces Institute of Pathology, Rawalpindi from July 2008 to December 2009.
  • OPG and CT scans of the head and neck region, chest X-rays, abdominal ultrasounds and liver function tests.
  • Size of the primary tumour, the size, number and laterality of the involved cervical lymph nodes and the presence/absence of distant metastases were documented and statistically analysed using SPSS-17.
  • The primary tumour was 4 Cm or more in size, (T3/T4) 71.25% of the cases.
  • Overall, clinical stage IV was the most common (57.18%) followed by stage III (24.55%), stage II (13.77%) and stage I (4.49%).
  • CONCLUSION: Oral cancers are diagnosed late (Stage III and IV) in Pakistan and need immediate public and professional attention.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnostic Imaging. Female. Humans. Liver Function Tests. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Pakistan / epidemiology. Retrospective Studies

  • Genetic Alliance. consumer health - Oral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22338419.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


22. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol; 2006 Oct;45(4):529-38
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.
  • BACKGROUND/AIMS: End-stage liver disease accounts for one in forty deaths worldwide.
  • Chronic infections with hepatitis B virus (HBV) and hepatitis C virus (HCV) are well-recognized risk factors for cirrhosis and liver cancer, but estimates of their contributions to worldwide disease burden have been lacking.
  • Applied to 2002 worldwide mortality estimates, these fractions represent 929,000 deaths due to chronic HBV and HCV infections, including 446,000 cirrhosis deaths (HBV: n=235,000; HCV: n=211,000) and 483,000 liver cancer deaths (HBV: n=328,000; HCV: n=155,000).
  • CONCLUSIONS: HBV and HCV infections account for the majority of cirrhosis and primary liver cancer throughout most of the world, highlighting the need for programs to prevent new infections and provide medical management and treatment for those already infected.
  • [MeSH-major] Global Health. Hepatitis B, Chronic / mortality. Hepatitis C, Chronic / mortality. Liver Cirrhosis / mortality. Liver Neoplasms / mortality
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Prevalence. Risk Factors. World Health Organization


23. Habermann JK, Paulsen U, Roblick UJ, Upender MB, McShane LM, Korn EL, Wangsa D, Krüger S, Duchrow M, Bruch HP, Auer G, Ried T: Stage-specific alterations of the genome, transcriptome, and proteome during colorectal carcinogenesis. Genes Chromosomes Cancer; 2007 Jan;46(1):10-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage-specific alterations of the genome, transcriptome, and proteome during colorectal carcinogenesis.
  • To identify sequential alterations of the genome, transcriptome, and proteome during colorectal cancer progression, we have analyzed tissue samples from 36 patients, including the complete mucosa-adenoma-carcinoma sequence from 8 patients.
  • Comparative genomic hybridization (CGH) revealed patterns of stage specific, recurrent genomic imbalances.
  • Gene expression analysis on 9K cDNA arrays identified 58 genes differentially expressed between normal mucosa and adenoma, 116 genes between adenoma and carcinoma, and 158 genes between primary carcinoma and liver metastasis (P < 0.001).
  • In conclusion, increasing genomic instability and a recurrent pattern of chromosomal imbalances as well as specific gene and protein expression changes correlate with distinct stages of colorectal cancer progression.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Aneuploidy. Female. Gene Expression Profiling. Humans. Male. Middle Aged. Models, Biological. Oligonucleotide Array Sequence Analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Wiley-Liss, Inc.
  • (PMID = 17044061.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proteome
  •  go-up   go-down


24. Lou HZ, Pan HM, Jin W: [Clinical study on treatment of primary liver cancer by Aidi injection combined with cool-tip radiofrequency ablation]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2007 May;27(5):393-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study on treatment of primary liver cancer by Aidi injection combined with cool-tip radiofrequency ablation].
  • OBJECTIVE: To investigate the therapeutic efficacy and adverse reactions of Aidi Injection (AI) combined with percutaneous cool-tip radiofrequency ablation (CRFA) in treatment of primary liver cancer and to explore its effect on immune function.
  • METHODS: Eighty-nine patients with primary liver cancer at middle-late stage were assigned to the control group with CRFA alone and the treatment group treated with CRFA and intravenous dripping of AI 50 mL once every day for succesive 20 days.
  • CONCLUSION: AI treatment could relieve the impairment of CRFA on hepatic function, improve immune function and reduce relapse rate in patients with primary liver cancer.

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17650788.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / aidi herbal drug
  •  go-up   go-down


25. Zhu Lz, Yang Rj: [Digital subtraction angiography manifestation and interventional therapy of arteriovenous shunting in primary hepatocellular carcinoma of advanced stage]. Beijing Da Xue Xue Bao; 2008 Apr;40(2):129-34
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Digital subtraction angiography manifestation and interventional therapy of arteriovenous shunting in primary hepatocellular carcinoma of advanced stage].
  • CONCLUSION: Primary hepatic carcinoma with AVS increases difficulty of interventional therapyìbut as long as we take active and proper treating measureìwe could acquire satisfactory curative effect without serious syndrome.
  • DSA can demonstrate the type, the site and the degree of AVS completely and directly, thus having important value in treating primary hepatic carcinoma and improving prognosis.
  • [MeSH-major] Angiography, Digital Subtraction. Arteriovenous Fistula / radiography. Arteriovenous Fistula / therapy. Chemoembolization, Therapeutic / methods. Liver Neoplasms / radiography
  • [MeSH-minor] Adult. Aged. Carcinoma, Hepatocellular / complications. Carcinoma, Hepatocellular / radiography. Female. Hepatic Artery / abnormalities. Humans. Male. Middle Aged. Portal Vein / abnormalities. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18458684.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


26. Patiutko IuI, Chuchuev ES, Kotel'nikov AG, Sagaĭdak IV, Badalian KhV: [Synchronous operations in metastatic cancer of the liver]. Khirurgiia (Mosk); 2006;(5):14-7
MedlinePlus Health Information. consumer health - Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Synchronous operations in metastatic cancer of the liver].
  • The resection of the liver has been performed in 661 patients including 154 (23.3%) cases of synchronous metastatic cancer of the liver.
  • Among the latter patients primary tumor was removed in one stage with liver resection in 56% cases.
  • Elderly age of the patients, multiple bilobular foci in the liver, size of the foci more than 10 cm, traumatic operations on the primary focus were not contraindications to synchronous operations.
  • Surgical treatment for colorectal cancer should be supplemented with adjuvant chemotherapy.
  • The long-term results demonstrate better survival after synchronous operations for colorectal cancer.
  • [MeSH-major] Liver Neoplasms / secondary. Liver Neoplasms / surgery. Surgical Procedures, Operative / methods
  • [MeSH-minor] Adult. Aged. Female. Gastrointestinal Neoplasms / pathology. Gastrointestinal Neoplasms / surgery. Humans. Male. Middle Aged. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16858334.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


27. Iizuka M, Sengoku N, Nakakuma T, Yoshimura N, Hayashi K, Enomoto T, Kuranami M, Watanabe M: [A case of stage IV breast cancer in which a long-term no change state (NC) was attained by a combination of S-1 and TAM following AC-T as a primary systemic therapy (PST)]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2228-30
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of stage IV breast cancer in which a long-term no change state (NC) was attained by a combination of S-1 and TAM following AC-T as a primary systemic therapy (PST)].
  • We here describe a case of advanced breast cancer (Stage IV) in which an oral S-1+TAM therapy following a primary systemic chemo-radiotherapy has been effective in maintaining the patient's QOL.
  • Subsequently, radiographic imaging tests revealed that the tumor had metastasized to the liver and lungs, as well as the skull.
  • Accordingly, a primary systemic chemotherapy (4 series of AC/T) was started and followed by local radiation therapy (60 Gys) immediately after completing the chemotherapy.
  • The metastasizing lesions in the liver, lungs, and skull had markedly reduced in the size and number, and the skin ulceration had healed up by these treatments.
  • She has been quite well without any adverse effects by S-1 and TAM, and the primary as well as metastasizing lesions remain stable with normalized tumor marker levels (NC) for nearly 3 years.
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. Biopsy. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Doxorubicin / therapeutic use. Drug Combinations. Female. Humans. Mitoxantrone / therapeutic use. Neoplasm Staging. Time Factors. Tomography, X-Ray Computed. Topotecan / therapeutic use

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106579.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Drug Combinations; 04079A1RDZ / Cytarabine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7M7YKX2N15 / Topotecan; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; P88XT4IS4D / Paclitaxel; AC protocol; TAM protocol
  •  go-up   go-down


28. Tanioka M, Katsumata N, Sasajima Y, Ikeda S, Kato T, Onda T, Kasamatsu T, Fujiwara Y: Clinical characteristics and outcomes of women with stage IV endometrial cancer. Med Oncol; 2010 Dec;27(4):1371-7
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and outcomes of women with stage IV endometrial cancer.
  • Treatment strategies for patients with stage IV endometrial cancer (EC) remain controversial.
  • We retrospectively analyzed the clinical characteristics and outcomes of 41 women with stage IV EC.
  • The results of preoperative cytologic evaluation and biopsy of the endometrium were reviewed by a single pathologist for patients in whom stage IV EC was diagnosed preoperatively.
  • Of the 41 patients with stage IV EC (median age, 62 years), 31 had surgical stage IV disease and 10 had clinical stage IV disease.
  • Twenty-eight patients were diagnosed of stage IV EC before surgery or without surgery.
  • Neither surgery as primary therapy nor optimal cytoreduction was significantly related to overall survival in either the 28 patients in whom stage IV was diagnosed preoperatively or in all 41 patients.
  • In women with stage IV EC, histologic features and extent of disease are more important determinants of outcomes than any kind of treatment.
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Bone Neoplasms / secondary. Bone Neoplasms / surgery. Carcinoma, Small Cell / secondary. Carcinoma, Small Cell / surgery. Cystadenocarcinoma, Serous / secondary. Cystadenocarcinoma, Serous / surgery. Female. Humans. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20024630.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


29. Nakamura T, Fuwa N, Kodaira T, Tachibana H, Tomoda T, Nakahara R, Inokuchi H: Clinical outcome of stage III non-small-cell lung cancer patients after definitive radiotherapy. Lung; 2008 Mar-Apr;186(2):91-6
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome of stage III non-small-cell lung cancer patients after definitive radiotherapy.
  • Primarily combined radiotherapy and chemotherapy are used to treat unresectable non-small-cell lung cancer; however, the results are not satisfactory.
  • From March 1999 to January 2004, 102 patients with stage IIIA/IIIB non-small-cell lung cancer received definitive radiotherapy with or without chemotherapy.
  • Maximal chemotherapy was given to patients with normal kidney, liver, and bone marrow functions.
  • Patients whose primary tumor is located in the superior lobe appear to have a better clinical outcome.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Dose-Response Relationship, Radiation. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasm Staging. Prognosis. Radiation Pneumonitis / prevention & control. Retrospective Studies. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives. Vindesine / administration & dosage


30. Clements D, Dhruva Rao P, Ramanathan D, Adams R, Maughan TS, Davies MM: Management of the asymptomatic primary in the palliative treatment of metastatic colorectal cancer. Colorectal Dis; 2009 Oct;11(8):845-8
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of the asymptomatic primary in the palliative treatment of metastatic colorectal cancer.
  • OBJECTIVE: The management of the asymptomatic primary in stage IV colorectal cancer presents a dilemma.
  • Nonresectional management of the primary is associated with the risks of obstruction, perforation or haemorrhage.
  • Our practice in patients with stage IV disease is palliative chemotherapy and symptom control.
  • We reviewed our nonoperatively managed patients with colorectal liver metastases in order to identify the percentage of patients requiring urgent operative interventions for symptoms related to the primary.
  • SUBJECTS/PATIENTS AND METHOD: A retrospective review of all patients treated for stage IV disease at our institution from 2003-2006 was undertaken.
  • There were no similarities between these three patients in terms of age, sex, site or stage of primary, volume of liver metastases, and alkaline phosphatase (ALP) or carcinoembryonic antigen (CEA) levels.
  • CONCLUSION: Of 37 patients initially treated palliatively for stage IV colorectal cancer, 92% required no surgical treatment of their primary.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Colorectal Neoplasms / drug therapy. Liver Neoplasms / secondary. Palliative Care
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Colorectal Dis. 2010 Mar;12(3):267; author reply 267-8 [20041926.001]
  • (PMID = 19175637.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating
  •  go-up   go-down


31. Hu JL, Huang JJ, Fu XH: [Survival status and prognostic factors of liver metastases from colorectal cancer]. Zhonghua Zhong Liu Za Zhi; 2010 Apr;32(4):286-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Survival status and prognostic factors of liver metastases from colorectal cancer].
  • OBJECTIVE: To analyze the survival status and prognostic factors of patients with liver metastases from colorectal cancer.
  • METHODS: The survival rate and prognostic factors of 112 patients with liver metastases from colorectal cancer, who had complete follow-up data, were retrospectively assessed by Kaplan-Meier analysis and multivariate regression analysis.
  • Univariate analysis demonstrated that gender, age, primary tumor site, chemotherapy and pathological types had no significant correlation with the overall survival.
  • But the treatment of primary tumor, time of liver metastasis, gross type of tumor, resection of liver metastases and clinical stage status were all independently related with the prognosis of patients.
  • Multivariate regression analysis showed that resection of liver metastases, gross type of tumor and clinical stage were key factors affecting the prognosis of patients with liver metastases from colorectal cancer.
  • CONCLUSION: Patients with advanced stage, infiltrative gross type of colorectal cancer should be followed-up closely so that liver metastases from the cancer can be diagnosed and treated early.
  • Resection of both the primary tumor and liver metastasis may improve survival of the patients.
  • [MeSH-major] Colonic Neoplasms / pathology. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Rectal Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / secondary. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Hepatectomy. Humans. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Retrospective Studies. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20510081.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


32. Tralhão JG, Hoti E, Serôdio M, Laranjeiro P, Paiva A, Abrantes AM, Pais ML, Botelho MF, Castro Sousa F: Perioperative tumor cell dissemination in patients with primary or metastatic colorectal cancer. Eur J Surg Oncol; 2010 Feb;36(2):125-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perioperative tumor cell dissemination in patients with primary or metastatic colorectal cancer.
  • INTRODUCTION: Although there is general correlation between the TNM stage of colorectal cancer (CRC) and its prognosis, there is often significant variability of tumor behaviour and individual patient outcome, which is unaccounted for by pathologic factors alone.
  • Our aim was to estimate perioperative tumor cell dissemination in patients with primary or CRC liver metastases as a possible factor influencing the outcome.
  • Sixteen patients (47%) had CRC liver metastases only.
  • The remaining six patients who underwent colon or liver resection for benign conditions, acted as the control group.
  • [MeSH-major] Colorectal Neoplasms / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Neoplastic Cells, Circulating / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Count. Colectomy / adverse effects. Female. Flow Cytometry. Hepatectomy / adverse effects. Humans. Male. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19646840.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


33. Liang SX, Zhu XD, Xu ZY, Zhu J, Zhao JD, Lu HJ, Yang YL, Chen L, Wang AY, Fu XL, Jiang GL: Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys; 2006 Jun 1;65(2):426-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance.
  • PURPOSE: To identify risk factors relevant to radiation-induced liver disease (RILD) and to determine the hepatic tolerance to radiation.
  • METHODS AND MATERIALS: The data of 109 primary liver carcinomas (PLC) treated with hypofractionated three-dimensional conformal radiation therapy (3D-CRT) were analyzed.
  • RESULTS: The risk factors for RILD were late T stage, large gross tumor volume, presence of portal vein thrombosis, association with Child-Pugh Grade B cirrhosis, and acute hepatic toxicity.
  • (1) Mean dose to normal liver (MDTNL) of 23 Gy was tolerable. (2) For cumulative dose-volume histogram, the tolerable volume percentages would be less than: V5 of 86%, V10 of 68%, V15 of 59%, V20 of 49%, V25 of 35%, V30 of 28%, V35 of 25%, and V40 of 20%. (3) Tolerable MDTNL could be estimated by MDTNL (Gy) = -1.686 + 0.023 * normal liver volume (cm3).
  • [MeSH-major] Liver / radiation effects. Liver Neoplasms / radiotherapy. Radiation Injuries / etiology. Radiation Tolerance / physiology. Radiotherapy, Conformal / adverse effects
  • [MeSH-minor] Adult. Aged. Carcinoma, Hepatocellular. Dose Fractionation. Female. Humans. Liver Cirrhosis / etiology. Liver Cirrhosis / pathology. Logistic Models. Male. Maximum Tolerated Dose. Middle Aged. Multivariate Analysis. Neoplasm Staging. ROC Curve. Risk Factors

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16690430.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


34. Boudreaux JP, Putty B, Frey DJ, Woltering E, Anthony L, Daly I, Ramcharan T, Lopera J, Castaneda W: Surgical treatment of advanced-stage carcinoid tumors: lessons learned. Ann Surg; 2005 Jun;241(6):839-45; discussion 845-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of advanced-stage carcinoid tumors: lessons learned.
  • OBJECTIVE: To evaluate clinical outcomes in a large group of advanced-stage carcinoid patients (stage IV) following multimodal surgical therapy.
  • SUMMARY BACKGROUND DATA: Patients with advanced-stage carcinoid have traditionally experienced poor 5-year survival (18%-30%).
  • Two- and four-year survival for patients with no or unilateral liver metastases (n = 23) was 89%, while 2- and 4-year survival for patients with bilateral liver disease (n = 59) was 68% and 52% (P = 0.072), respectively.
  • CONCLUSION: We think that all patients with advanced-stage carcinoid should be evaluated for possible multimodal surgical therapy.
  • Primary tumors should be resected, even in the presence of distant metastases to prevent future intestinal obstruction.
  • The "wait and see" method of management of this slow-growing cancer no longer has merit.
  • [MeSH-minor] Adolescent. Adult. Aged. Algorithms. Antineoplastic Agents, Hormonal / administration & dosage. Chemoembolization, Therapeutic. Female. Humans. Intestinal Obstruction / etiology. Liver Neoplasms / secondary. Male. Malignant Carcinoid Syndrome / etiology. Middle Aged. Neoplasm Staging. Octreotide / administration & dosage. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Surg. 2002 Aug;68(8):667-71; discussion 671-2 [12206599.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):469-81 [14713260.001]
  • [Cites] J Gastrointest Surg. 2004 Sep-Oct;8(6):742-56 [15358337.001]
  • [Cites] Surgery. 1990 Dec;108(6):1091-6 [1701060.001]
  • [Cites] Am J Surg. 1995 May;169(5):523-8 [7747834.001]
  • [Cites] World J Surg. 1996 Sep;20(7):908-14; discussion 914-5 [8678970.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):463-8 [14713259.001]
  • [Cites] J Am Coll Surg. 1998 Jul;187(1):88-92; discussion 92-3 [9660030.001]
  • [Cites] Ann Oncol. 2004 Jun;15(6):966-73 [15151956.001]
  • [Cites] Ann Surg. 2003 Jun;237(6):790-8; discussion 798-800 [12796575.001]
  • [Cites] Surgery. 2003 Dec;134(6):1057-63; discussion 1063-5 [14668741.001]
  • [Cites] Am J Surg. 2004 Jan;187(1):39-46 [14706584.001]
  • [Cites] Surgery. 2001 Oct;130(4):677-82; discussion 682-5 [11602899.001]
  • (PMID = 15912033.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; RWM8CCW8GP / Octreotide
  • [Other-IDs] NLM/ PMC1357164
  •  go-up   go-down


35. Sun Y, Shang G, Bao YX, Zhang H: [Prognostic analysis of 77 cases of rectal cancer with synchronous liver metastases]. Zhonghua Zhong Liu Za Zhi; 2010 Aug;32(8):622-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic analysis of 77 cases of rectal cancer with synchronous liver metastases].
  • OBJECTIVE: To explore the prognostic factors for rectal cancer patients with synchronous liver metastases.
  • METHODS: Data from a total of 77 cases of rectal cancer with synchronous liver metastases treated in our center from January 2002 to December 2008 were collected and reviewed.
  • Univariate analysis with Kaplan-Meier method revealed that the differentiation of the primary tumor, T-stage, N status, the distribution, number and size of liver metastases, extrahepatic disease, serum CEA level at diagnosis and treatment modality were prognostic factors (P < 0.05).
  • Multivariate analysis showed that the differentiation of the primary tumor (P = 0.007), T-stage (P = 0.027), the size of liver metastases (P = 0.003), serum CEA value at diagnosis (P = 0.000) were independent prognostic factors for rectal cancer patients with synchronous liver metastases.
  • CONCLUSION: The factors affecting the prognosis for rectal cancer patients with synchronous liver metastases are the differentiation of the primary tumor, T-stage, N status, the distribution, number and size of liver metastases, extrahepatic disease, serum CEA level at diagnosis and treatment modality.
  • The differentiation of the primary tumor, T-stage, the size of liver metastases, and serum CEA value at diagnosis are independent prognostic factors.
  • [MeSH-major] Carcinoembryonic Antigen / blood. Liver Neoplasms / secondary. Rectal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Proportional Hazards Models. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21122418.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


36. Fang H, Wang XY, Wang JW, Zhang HG, Feng FY, Shi YK: [Analysis of prognostic factors in 300 colorectal cancer patients with liver metastases]. Zhonghua Zhong Liu Za Zhi; 2009 Mar;31(3):220-2
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of prognostic factors in 300 colorectal cancer patients with liver metastases].
  • OBJECTIVE: To analyse the clinical characteristics and potential prognostic factors of colorectal cancer patients with liver metastases.
  • METHODS: The clinical and pathological data of 300 colorectal cancer patients with liver metastases were retrospectively reviewed and analyzed.
  • The 1-, 2- and 5-year survival rates after liver metastases were 79.0%, 29.0% and 3.0%, respectively.
  • Univariate analysis revealed that performance status (KPS), histological grading, primary tumor, N status, lymphatic and vascular invasion, stage at diagnosis, the number, size and distribution of liver metastases and other accompanied metastases were prognostic factors.
  • Multivariate analysis showed that KPS, lymphatic and vascular invasion, the number and size of liver metastases were independent prognostic factors of colorectal cancer with liver metastases.
  • CONCLUSION: Performance status, lymphatic and vascular invasion, the number and size of liver metastases are independent prognostic factors of colorectal cancer with liver metastases.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Liver Neoplasms / secondary. Rectal Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / secondary. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Neoplastic Cells, Circulating. Proportional Hazards Models. Retrospective Studies. Survival Rate. Tumor Burden. Young Adult

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615265.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


37. Kehoe SM, Zivanovic O, Ferguson SE, Barakat RR, Soslow RA: Clinicopathologic features of bone metastases and outcomes in patients with primary endometrial cancer. Gynecol Oncol; 2010 May;117(2):229-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features of bone metastases and outcomes in patients with primary endometrial cancer.
  • OBJECTIVE: Patients with advanced or recurrent endometrial cancer often have distant metastases found within the lymph nodes, liver, and/or lung.
  • However, there have been reported cases of primary endometrial cancer with metastasis to the bone.
  • The objective of this study was to describe the clinical and pathologic features of endometrial cancer metastatic to bone.
  • METHODS: A retrospective chart review of our clinical and pathology database was performed to identify women diagnosed with endometrial cancer metastatic to the bone between 1990 and 2007.
  • RESULTS: Twenty-one patients with endometrial cancer metastatic to the bone were identified; in 12 patients (57%), the diagnosis was confirmed by a bone biopsy.
  • The median age of diagnosis of primary endometrial cancer was 60 years (range, 32-84).
  • Fourteen patients (67%) had FIGO stage III/IV disease.
  • The overall survival of those patients with bone metastases at primary diagnosis was 17 months (95% CI: 2-32) compared to 32 months (95% CI: 14-49) for those with a recurrent bone metastasis.
  • CONCLUSION: Although a rare event, endometrial cancer can metastasize to the bone.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20199802.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Kleespies A, Füessl KE, Seeliger H, Eichhorn ME, Müller MH, Rentsch M, Thasler WE, Angele MK, Kreis ME, Jauch KW: Determinants of morbidity and survival after elective non-curative resection of stage IV colon and rectal cancer. Int J Colorectal Dis; 2009 Sep;24(9):1097-109
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determinants of morbidity and survival after elective non-curative resection of stage IV colon and rectal cancer.
  • PURPOSE: The benefit of elective primary tumor resection for non-curable stage IV colorectal cancer (CRC) remains largely undefined.
  • METHODS: Using a prospective database, we analyzed potential risk factors in 233 patients, who were electively operated for non-curable stage IV CRC between 1996 and 2002.
  • RESULTS: Patients with colon cancer (CC = 156) and rectal cancer (RC = 77) were comparable with regard to age, sex, comorbidity, American Society of Anesthesiologists score, carcinoembryonic antigen levels, hepatic spread, tumor grade, resection margins, 30-day mortality (CC 5.1%, RC 3.9%) and postoperative chemotherapy. pT4 tumors, carcinomatosis, and non-anatomical resections were more common in colon cancer patients, whereas enterostomies (CC 1.3%, RC 67.5%, p < 0.0001), anastomotic leaks (CC 7.7%, RC 24.2%, p = 0.002), and total surgical complications (CC 19.9%, RC 40.3%, p = 0.001) were more frequent after rectal surgery.
  • Independent determinants of an increased postoperative morbidity were primary rectal cancer, hepatic tumor load >50%, and comorbidity >1 organ.
  • CONCLUSIONS: Palliative resection is associated with a particularly unfavorable outcome in rectal cancer patients presenting with a locally advanced tumor (pT4, expected R2 resection) or an extensive comorbidity, and in all CRC patients who show a hepatic tumor load >50%.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Comorbidity. Female. Humans. Liver Neoplasms. Male. Middle Aged. Morbidity. Prognosis. Risk Assessment. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19495779.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


39. Owens BM, Hawley TS, Spain LM, Kerkel KA, Hawley RG: TLX1/HOX11-mediated disruption of primary thymocyte differentiation prior to the CD4+CD8+ double-positive stage. Br J Haematol; 2006 Jan;132(2):216-29
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TLX1/HOX11-mediated disruption of primary thymocyte differentiation prior to the CD4+CD8+ double-positive stage.
  • Interestingly, enforced expression of TLX1 disrupted the differentiation of murine fetal liver precursors and human cord blood CD34(+) stem/progenitor cells prior to the DP thymocyte stage.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1995 Oct 5;11(7):1333-8 [7478554.001]
  • [Cites] Science. 1995 Sep 29;269(5232):1875-7 [7569929.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Oct 24;92(22):10302-6 [7479772.001]
  • [Cites] Gene Ther. 1994 Mar;1(2):136-8 [7584069.001]
  • [Cites] Biochemistry. 1995 Nov 7;34(44):14601-8 [7578067.001]
  • [Cites] Cell. 1996 Apr 5;85(1):27-37 [8620534.001]
  • [Cites] Blood. 1996 Mar 15;87(6):2180-6 [8630377.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10297-302 [8816794.001]
  • [Cites] Cancer Res. 1997 Jan 15;57(2):337-45 [9000579.001]
  • [Cites] Nature. 1997 Jan 30;385(6615):454-8 [9009195.001]
  • [Cites] Immunity. 1997 Mar;6(3):265-72 [9075927.001]
  • [Cites] Cell. 1997 Jun 27;89(7):1011-9 [9215624.001]
  • [Cites] Cell. 1997 Jun 27;89(7):1033-41 [9215626.001]
  • [Cites] Gene Ther. 1997 Oct;4(10):1013-22 [9415306.001]
  • [Cites] J Immunol. 1998 Jun 15;160(12):5735-41 [9637482.001]
  • [Cites] Blood. 1998 Aug 1;92(3):877-87 [9680355.001]
  • [Cites] Immunity. 1999 May;10(5):537-46 [10367899.001]
  • [Cites] J Immunol. 1999 Aug 1;163(3):1334-41 [10415032.001]
  • [Cites] Blood. 2004 Dec 15;104(13):4173-80 [15054041.001]
  • [Cites] Oncogene. 2005 Apr 18;24(17):2899-908 [15838523.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4849-52 [15713800.001]
  • [Cites] Blood. 2005 Jul 1;106(1):274-86 [15774621.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1705-8 [15990867.001]
  • [Cites] Oncogene. 2005 Aug 25;24(36):5561-75 [15897879.001]
  • [Cites] Mol Ther. 2000 Nov;2(5):458-69 [11082319.001]
  • [Cites] J Immunol. 2001 Feb 15;166(4):2209-17 [11160274.001]
  • [Cites] Stem Cells. 2001;19(2):118-24 [11239166.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):609-14 [11149941.001]
  • [Cites] Ann N Y Acad Sci. 2000;917:724-31 [11268400.001]
  • [Cites] Leuk Lymphoma. 2000 Oct;39(3-4):241-56 [11342305.001]
  • [Cites] J Exp Med. 2001 Jun 18;193(12):1431-7 [11413198.001]
  • [Cites] J Exp Med. 2001 Jul 2;194(1):99-106 [11435476.001]
  • [Cites] Nature. 2001 Sep 6;413(6851):86-91 [11544531.001]
  • [Cites] J Immunol. 2002 Mar 1;168(5):2325-31 [11859122.001]
  • [Cites] Curr Opin Immunol. 2002 Apr;14(2):200-6 [11869893.001]
  • [Cites] Oncogene. 2002 May 13;21(21):3475-95 [12032783.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] J Immunol. 2002 Sep 15;169(6):3021-9 [12218117.001]
  • [Cites] Stem Cells. 2002;20(5):364-79 [12351808.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3828-31 [12393673.001]
  • [Cites] Nat Rev Immunol. 2002 Nov;2(11):888-97 [12415312.001]
  • [Cites] J Biol Chem. 2002 Nov 29;277(48):46289-97 [12228235.001]
  • [Cites] Trends Immunol. 2003 Apr;24(4):197-206 [12697452.001]
  • [Cites] Leukemia. 2003 May;17(5):887-93 [12750702.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4966-74 [12586625.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1851-7 [12970786.001]
  • [Cites] Cancer Cell. 2003 Oct;4(4):311-9 [14585358.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1909-11 [14604958.001]
  • [Cites] Lancet. 2004 Feb 14;363(9408):535-6 [14975618.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] J Immunol. 2004 May 1;172(9):5230-9 [15100261.001]
  • [Cites] J Exp Med. 2004 Sep 6;200(5):659-69 [15353558.001]
  • [Cites] Nat Genet. 2004 Oct;36(10):1084-9 [15361874.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Methods Mol Med. 2005;105:311-22 [15492404.001]
  • [Cites] Science. 1991 Jul 5;253(5015):79-82 [1676542.001]
  • [Cites] Semin Immunol. 1990 Jan;2(1):51-8 [2129901.001]
  • [Cites] EMBO J. 1991 Oct;10(10):2905-10 [1717256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):8900-4 [1681546.001]
  • [Cites] Blood. 1991 Dec 1;78(11):2996-3003 [1683261.001]
  • [Cites] Cell. 1991 Nov 29;67(5):889-99 [1959134.001]
  • [Cites] J Immunol. 1993 May 15;150(10):4244-52 [8387091.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 May 15;90(10):4431-5 [8099440.001]
  • [Cites] J Immunol. 1993 Jul 1;151(1):83-91 [8326141.001]
  • [Cites] J Immunol. 1993 Sep 1;151(5):2546-54 [8360476.001]
  • [Cites] Oncogene. 1994 Jan;9(1):1-12 [7905617.001]
  • [Cites] Immunology. 1994 Jan;81(1):115-9 [8132207.001]
  • [Cites] J Immunol Methods. 1994 Apr 15;170(2):145-57 [8157993.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1587-93 [7520780.001]
  • [Cites] J Exp Med. 1994 Nov 1;180(5):1955-60 [7964471.001]
  • [Cites] Nature. 1995 Mar 2;374(6517):70-4 [7870176.001]
  • [Cites] Immunity. 1994 Jul;1(4):261-7 [7889413.001]
  • (PMID = 16398656.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01HL65519; United States / NHLBI NIH HHS / HL / R01 HL066305-05; United States / NCRR NIH HHS / RR / R24RR16209; United States / NHLBI NIH HHS / HL / R01 HL065519; United States / NHLBI NIH HHS / HL / R01 HL066305; United States / NCRR NIH HHS / RR / R24 RR016209; United States / NHLBI NIH HHS / HL / HL066305-05; United States / NHLBI NIH HHS / HL / R01HL66305
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Proto-Oncogene Proteins; 143275-75-6 / TLX1 protein, human
  • [Other-IDs] NLM/ NIHMS51706; NLM/ PMC2431114
  •  go-up   go-down


40. Aletti GD, Dowdy SC, Podratz KC, Cliby WA: Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system. Gynecol Oncol; 2007 Apr;105(1):84-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system.
  • OBJECTIVES: Determine impact of tumor distribution and surgery on prognosis in patients with stage IV epithelial ovarian cancer (EOC).
  • METHODS: Retrospective analysis of stage IV EOC patients undergoing primary surgery between 1994 and 1998.
  • A very high risk group of patients based on extent of peritoneal disease, parenchymal liver metastases and ASA could be identified in whom the rate of optimal debulking was less than 25% (median survival 1.4 years).
  • No patients with multiple liver metastases were optimally cytoreduced and the median survival was 1 year.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Paclitaxel / administration & dosage. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17157903.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


41. Ishigami S, Natsugoe S, Nakajo A, Matsumoto M, Uenosono Y, Arigami T, Setoyama T, Arima H, Uchikado Y, Kita Y, Sasaki K, Aikou T: Salvage gastrectomy following a combination of biweekly paclitaxel and S-1 for stage IV gastric cancer. J Gastrointest Surg; 2008 Aug;12(8):1370-5
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage gastrectomy following a combination of biweekly paclitaxel and S-1 for stage IV gastric cancer.
  • BACKGROUND AND AIM: We investigated the clinical benefits of salvage gastrectomy for stage IV gastric cancer patients whose distant lesions showed complete response after chemotherapy.
  • METHODS: We enrolled 18 stage IV gastric cancer patients whose distant metastases had disappeared or were controlled by a combination of biweekly paclitaxel (PTX) and S-1.
  • RESULTS: Of the 18 patients, 8 had distant lymph node metastases, 9 had peritoneal dissemination, and five had multiple liver metastases prior to chemotherapy.
  • Pathological evaluation revealed grade 3 and grade 2 tumor regression in the primary lesion in one and five patients, respectively, and grade 3 and grade 2 tumor regression in the lymph nodes in one and six patients, respectively.
  • CONCLUSION: R0 salvage gastrectomy following a combination of biweekly PTX and S-1 may have significant clinical efficacy for advanced gastric cancer patients.
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Drug Combinations. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18516651.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


42. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YX, Shao JY: MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA; 2008 Nov;14(11):2348-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis.
  • To investigate the global expression profile of miRNAs in primary breast cancer (BC) and normal adjacent tumor tissues (NATs) and its potential relevance to clinicopathological characteristics and patient survival, the genome-wide expression profiling of miRNAs in BC was investigated using a microarray containing 435 mature human miRNA oligonucleotide probes.
  • Interestingly, among the 113 BC cases, high level expression of miR-21 was significantly correlated with advanced clinical stage (P = 0.006, Fisher's exact text), lymph node metastasis (P = 0.007, Fisher's exact text), and shortened survival of the patients (hazard ratio [HR]=5.476, P < 0.001).
  • Multivariate Cox regression analysis revealed this prognostic impact (HR=4.133, P = 0.001) to be independent of disease stage (HR=2.226, P = 0.013) and histological grade (HR=3.681, P = 0.033).
  • This study could identify the differentiated miRNAs expression profile in BC and reveal that miR-21 overexpression was correlated with specific breast cancer biopathologic features, such as advanced tumor stage, lymph node metastasis, and poor survival of the patients, indicating that miR-21 may serve as a molecular prognostic marker for BC and disease progression.
  • [MeSH-minor] Adult. Aged. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Res. 2008 Mar;18(3):350-9 [18270520.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):189-98 [16530703.001]
  • [Cites] Cancer Treat Rev. 2001 Jun;27(3):137-42 [11417963.001]
  • [Cites] Bioinformatics. 2001;17 Suppl 1:S49-55 [11472992.001]
  • [Cites] Science. 2001 Oct 26;294(5543):853-8 [11679670.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Am J Clin Pathol. 2002 Sep;118(3):408-17 [12219783.001]
  • [Cites] Lancet. 2003 Mar 15;361(9361):923-9 [12648972.001]
  • [Cites] Cell. 2003 Jun 13;113(6):673-6 [12809598.001]
  • [Cites] Surg Clin North Am. 2003 Aug;83(4):803-19 [12875597.001]
  • [Cites] Nucleic Acids Res. 2004;32(4):e43 [14985473.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3753-6 [15172979.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60 [15284443.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32 [15738415.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Cancer. 2005 May 1;103(9):1770-7 [15770691.001]
  • [Cites] Nat Methods. 2004 Oct;1(1):47-53 [15782152.001]
  • [Cites] Nat Methods. 2004 Nov;1(2):155-61 [15782179.001]
  • [Cites] Semin Liver Dis. 2005;25(2):212-25 [15918149.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):828-33 [15944707.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Cell. 2005 Jul 15;122(1):6-7 [16009126.001]
  • [Cites] Nat Med. 2005 Jul;11(7):712-4 [16015356.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6029-33 [16024602.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Sep 9;334(4):1351-8 [16039986.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7065-70 [16103053.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19075-80 [16365291.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D140-4 [16381832.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Cell. 2006 Mar 24;124(6):1169-81 [16564011.001]
  • [Cites] RNA. 2006 May;12(5):913-20 [16540696.001]
  • [Cites] Mol Cancer. 2006;5:24 [16784538.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4677-84 [16966691.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2006 Jun;28(6):438-40 [17152490.001]
  • [Cites] Oncogene. 2007 Apr 26;26(19):2799-803 [17072344.001]
  • [Cites] JAMA. 2007 May 2;297(17):1901-8 [17473300.001]
  • [Cites] J Biol Chem. 2007 May 11;282(19):14328-36 [17363372.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4944-51 [17327404.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6092-9 [17616664.001]
  • [Cites] BMC Biotechnol. 2007;7:36 [17603869.001]
  • (PMID = 18812439.001).
  • [ISSN] 1469-9001
  • [Journal-full-title] RNA (New York, N.Y.)
  • [ISO-abbreviation] RNA
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MIRN21 microRNA, human; 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC2578865
  •  go-up   go-down


43. Ziarkiewicz-Wroblewska B, Gornicka B, Suleiman W, Wroblewski T, Morton M, Wilczynski GM, Heleniak H, Skwarek A, Koperski L, Dudek K, Krawczyk M, Jedrzejczak WW, Dwilewicz-Trojaczek J, Wasiutynski A: Primary lymphoma of the liver -- morphological and clinical analysis of 6 cases. Success of aggressive treatment. Neoplasma; 2005;52(3):267-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of the liver -- morphological and clinical analysis of 6 cases. Success of aggressive treatment.
  • Histological, clinical and immunohistochemical analysis of 6 cases of primary liver lymphomas (PLL) are presented.
  • PLL represents 4.3% of primary malignant liver tumors diagnosed in our department.
  • There were no signs of scirrhosis, and cancer markers were normal.
  • Despite clinically advanced stage at the time of diagnosis, if treated appropriately, the primary lymphoma of the liver has relatively good prognosis (five of our patients are alive).
  • [MeSH-major] Liver Neoplasms / diagnosis. Liver Neoplasms / surgery. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD59 / metabolism. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Immunohistochemistry. Male. Prognosis. Proto-Oncogene Proteins c-bcl-2 / metabolism. Proto-Oncogene Proteins c-myc / metabolism. Stem Cell Transplantation. bcl-2-Associated X Protein

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15875091.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antigens, CD59; 0 / Antineoplastic Agents; 0 / BAX protein, human; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-myc; 0 / bcl-2-Associated X Protein
  •  go-up   go-down


44. Li XP, Meng ZQ, Guo WJ, Li J: Treatment for liver metastases from breast cancer: results and prognostic factors. World J Gastroenterol; 2005 Jun 28;11(24):3782-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment for liver metastases from breast cancer: results and prognostic factors.
  • AIM: Liver metastases from breast cancer (BCLM) are associated with poor prognosis.
  • We report the results of TACE and systemic chemotherapy for patients with liver metastases from breast cancer and evaluate the prognostic factors.
  • METHODS: Forty-eight patients with liver metastases, from proved breast primary cancer were treated with TACE or systemic chemotherapy between January 1995 and December 2000.
  • According to univariate analysis, variables significantly associated with survival were the lymph node status of the primary cancer, the clinical stage of liver metastases, the Child-Pugh grade, loss of weight.
  • Other factors such as age, the intervals between the primary to the metastases, the maximal diameter of the liver metastases, the number of liver metastases, extrahepatic metastasis showed no prognostic significances.
  • These factors mentioned above such as the lymph node status of the primary cancer, the clinical stage of liver metastases, the Child-Pugh grade, loss of weight were also independent factors in multivariate analysis.
  • CONCLUSION: TACE treatment of liver metastases from breast cancer may prolong survival in certain patients.
  • This approach offers new promise for the curative treatment of the patients with metastatic breast cancer.
  • [MeSH-major] Breast Neoplasms / pathology. Chemoembolization, Therapeutic. Liver Neoplasms / secondary. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Humans. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] World J Gastroenterol. 2005 Nov 28;11(44):7057 [16437619.001]
  • (PMID = 15968739.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC4316035
  •  go-up   go-down


45. Yuan RH, Jeng YM, Pan HW, Hu FC, Lai PL, Lee PH, Hsu HC: Overexpression of KIAA0101 predicts high stage, early tumor recurrence, and poor prognosis of hepatocellular carcinoma. Clin Cancer Res; 2007 Sep 15;13(18 Pt 1):5368-76
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of KIAA0101 predicts high stage, early tumor recurrence, and poor prognosis of hepatocellular carcinoma.
  • EXPERIMENTAL DESIGN: KIAA0101 mRNA was measured by reverse transcription-PCR in 216 resected, unifocal, primary HCCs and its protein in 164 cases by immunohistochemistry.
  • KIAA0101 mRNA overexpression correlated with higher tumor grade (P = 0.0001), higher tumor stage with vascular invasion and various extents of intrahepatic spread (P = 1 x 10(-8)), ETR (P = 1.8 x 10(-6)), and lower 5-year survival (P = 0.0026).
  • Multivariate analysis confirmed that KIAA0101 overexpression was an independent risk factor associated with high-grade tumor (P = 0.0001), high-stage tumor (P < 0.0001), and ETR (P = 0.0052) and thus contributed to poor prognosis.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Carrier Proteins / metabolism. Liver Neoplasms / pathology. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. RNA, Messenger / analysis. RNA, Messenger / metabolism. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism. Up-Regulation

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875765.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / KIAA0101 protein, human; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


46. Lim MC, Kang S, Lee KS, Han SS, Park SJ, Seo SS, Park SY: The clinical significance of hepatic parenchymal metastasis in patients with primary epithelial ovarian cancer. Gynecol Oncol; 2009 Jan;112(1):28-34
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical significance of hepatic parenchymal metastasis in patients with primary epithelial ovarian cancer.
  • OBJECTIVE: The objective of this study was to determine the clinical significance of hepatic parenchymal metastasis on survival in patients with advanced epithelial ovarian cancer.
  • METHODS: We conducted a retrospective review of ovarian cancer patients with stages IIIc and IV hepatic parenchymal metastasis who were treated at the National Cancer Center in Korea between January 2001 and January 2008.
  • The stage IIIc group included 97 patients, and the group with stage IV disease and hepatic parenchymal metastasis included 16 patients.
  • Age, tumor grade, histology, serum CA-125 level, and the rate of optimal debulking were similar in patients with stage IIIc disease and patients with stage IV disease who had resectable, hepatic parenchymal metastasis from peritoneal seeding.
  • The 5-year progression free survival rate and the 5-year overall survival rate for patients with stage IIIc disease and patients with stage IV disease and hepatic parenchymal metastasis from peritoneal seeding were 25 and 23% (p=0.8063), and 55 and 51% (p=0.5671), respectively.
  • [MeSH-major] Liver Neoplasms / secondary. Liver Neoplasms / surgery. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Retrospective Studies

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2009 Nov;115(2):319; author reply 319-20 [19446315.001]
  • (PMID = 19010521.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


47. Kim H, Ahn YC, Park HC, Lim DH, Nam H: Results and prognostic factors of hypofractionated stereotactic radiation therapy for primary or metastatic lung cancer. J Thorac Oncol; 2010 Apr;5(4):526-32
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results and prognostic factors of hypofractionated stereotactic radiation therapy for primary or metastatic lung cancer.
  • INTRODUCTION: Retrospective analyses were performed on the patients with primary or metastatic lung cancer, who were treated with hypofractionated stereotactic radiation therapy (HSRT).
  • METHODS: HSRT was applied to 43 patients since 2001 till 2007: 16 patients were with stage I primary lung cancer and 27 were with metastasis.
  • The 5-year local progression-free survival and cancer-specific survival rate were 89.4 and 53.3%, respectively.
  • CONCLUSIONS: In HSRT for primary or metastatic lung cancers, smaller tumor size was significant prognostic factor for higher local control.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radiotherapy. Gastrointestinal Neoplasms / radiotherapy. Head and Neck Neoplasms / radiotherapy. Liver Neoplasms / radiotherapy. Lung Neoplasms / radiotherapy. Radiotherapy Planning, Computer-Assisted
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Dose Fractionation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome


48. Taniai N, Akimaru K, Yoshida H, Tajiri T: Surgical treatment for better prognosis of patients with liver metastases from colorectal cancer. Hepatogastroenterology; 2007 Sep;54(78):1805-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment for better prognosis of patients with liver metastases from colorectal cancer.
  • BACKGROUND/AIMS: Hepatic resection is established as the best available treatment for colorectal cancer metastases to the liver, but the optimal procedure for the resection is now controversial.
  • METHODOLOGY: A population of 111 patients with liver metastases from colorectal cancer underwent initial and radical hepatic resection.
  • Survival rates as a function of clinical, primary tumor pathologic TNM classification and surgical determinates were examined retrospectively with univariate and multivariate analyses.
  • Patient survival was uncorrelated with any of the following factors: sex, age, temporal relationship, primary tumor site, tumor stage, pathological depth, pathological vascular invasion, pathological lymphatic invasion and pathological lymph node metastases of the primary tumor, maximum diameter of liver lesions, intrahepatic distribution patterns, type of hepatectomy, and number of hepatectomies.
  • However, the number of liver tumors and the tumor-free margins were significantly associated with good prognosis.
  • [MeSH-major] Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Digestive System Surgical Procedures / methods. Hepatectomy / methods. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Retrospective Studies. Time Factors. Treatment Outcome


49. Konishi K, Hasegawa N, Kaneko H, Iimura Y, Shoji Y, Kawabata M: [Two cases of breast cancer responding to primary systemic chemotherapy containing trastuzumab without surgery]. Gan To Kagaku Ryoho; 2010 Jan;37(1):115-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of breast cancer responding to primary systemic chemotherapy containing trastuzumab without surgery].
  • She was diagnosed as invasive ductal carcinoma (T2N0M0, Stage IIA).
  • After primary systemic chemotherapy with 6 courses of 5-fluorouracil+epirubicin+cyclophosphamide(FEC)and 3 courses of weekly paclitaxel (PTX)+trastuzumab, the efficacy of chemotherapy was judged as a complete response (CR).
  • At 21 months after CR, local efficacy was judged as CR, but liver and bone metastases appeared, and were treated by capecitabine and trastuzumab.
  • She was diagnosed as invasive lobular carcinoma (T2N0M0, Stage IIA).
  • After primary systemic chemotherapy with 4 courses of FEC and 6 courses of docetaxel+trastuzumab, the efficacy of chemotherapy was judged as CR.
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Combined Modality Therapy. Female. Humans. Trastuzumab

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20087043.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; P188ANX8CK / Trastuzumab
  •  go-up   go-down


50. Belev N, Takorov I, Dimov P, Vladov N, Penov V: Aggressive surgery in the multimodality treatment of liver metastases from colorectal cancer. J BUON; 2007 Apr-Jun;12(2):209-13
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive surgery in the multimodality treatment of liver metastases from colorectal cancer.
  • PURPOSE: The purpose of this study was to analyze the impact of aggressive surgery concerning resection of liver metastases (LMs) from colorectal cancer (CRC) on morbidity, mortality and survival rates and to establish the benefits of multimodal strategies in increasing the resectability rates of LMs.
  • Thirty-four (18.4%) of them had LMs at the time of initial diagnosis, and 26 patients developed LMs in a certain period of time after resection of the primary CRC.
  • RESULTS: 44 resections were performed in 29 patients: one-stage resection of the primary CRC and the LMs in 15 (40%) cases, resection and thermoablation after adjuvant chemotherapy in 2 (4.3%), resection after neoadjuvant chemotherapy in 8 (17.2%), two-stage liver resection in 1 (2.15%), resection after recurrence or because of a newfound LM in 3 (6.45%).
  • Five resections of metastases larger than 5 cm, and 4 resections of 4 or more liver metastases were performed.
  • Morbidity rate was 15.9% (bile leakage in 4 patients, liver abscess in 1 and wound disruption in 2).
  • [MeSH-major] Colorectal Neoplasms / pathology. Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Survival Rate

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17600874.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


51. Siriwardana RC, Wijesuriya SR, Kumarage SK, Deen KI: Synchronous liver metastasis in colorectal cancer in Sri Lanka. Indian J Gastroenterol; 2010 Jul;29(4):149-51
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous liver metastasis in colorectal cancer in Sri Lanka.
  • OBJECTIVE: To assess the incidence of synchronous colorectal liver metastasis in patients referred to a tertiary referral center in Sri Lanka and to evaluate the differences in the clinicopathological features of patients with and without synchronous metastasis.
  • In the two groups macroscopic features compared were: tumor size (2 cm, 2-5 cm, and >5 cm), site of primary tumor and side of liver involved.
  • RESULTS: The rectum was the primary site of the tumor in a majority (60%) of patients.
  • There was no difference in the distribution of the primary site and size of the tumor, pathological stage, lymphatic infiltration and the degree of tumor differentiation in two groups (p > 0.05).
  • CONCLUSION: The incidence of synchronous colorectal liver metastasis seems to be lower in our patients.
  • Association of higher CEA level, advanced nodal stage and presence of vascular invasion needs to be further assessed with risk of developing metachronous liver metastasis.
  • [MeSH-major] Colorectal Neoplasms / pathology. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Female. Humans. Incidence. Male. Middle Aged. Retrospective Studies. Sri Lanka / epidemiology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20740338.001).
  • [ISSN] 0975-0711
  • [Journal-full-title] Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
  • [ISO-abbreviation] Indian J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


52. Park IJ, Kim HC, Yu CS, Kim PN, Won HJ, Kim JC: Radiofrequency ablation for metachronous liver metastasis from colorectal cancer after curative surgery. Ann Surg Oncol; 2008 Jan;15(1):227-32
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation for metachronous liver metastasis from colorectal cancer after curative surgery.
  • BACKGROUND: We compared outcomes of surgery and radiofrequency thermal ablation (RFA) in patients with metachronous liver metastases.
  • METHODS: Between October 1995 and December 2005, 59 patients underwent hepatic resection and 30 underwent RFA for metachronous liver metastases.
  • RESULTS: The two groups had similar mean age, sex ratio, comorbid medical conditions, primary disease stage, and frequency of solitary metastases.
  • CONCLUSIONS: Compared with hepatic resection, RFA for metachronous hepatic metastases from colorectal cancer was associated with higher local recurrence and shorter recurrence-free and overall survival rates, even in patients with solitary, small (</=3 cm) lesions.
  • [MeSH-major] Catheter Ablation. Colorectal Neoplasms / surgery. Hepatectomy. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiology, Interventional. Retrospective Studies. Risk Assessment. Survival Rate. Treatment Outcome


53. Suzuki S, Sasajima K, Sato Y, Watanabe H, Matsutani T, Iida S, Hosone M, Tsukui T, Maeda S, Shimizu K, Tajiri T: MAGE-A protein and MAGE-A10 gene expressions in liver metastasis in patients with stomach cancer. Br J Cancer; 2008 Jul 22;99(2):350-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MAGE-A protein and MAGE-A10 gene expressions in liver metastasis in patients with stomach cancer.
  • Tumour samples from 71 patients with stomach cancer, 41 patients with liver metastasis (group A) and 15 patients each in stages II-IV (group B) and stage I (group C) without liver metastasis were analysed.
  • MAGE-A10 mRNA expression in liver metastasis was found in eight (88.9%) out of nine patients.
  • The concordant rate between MAGE-A family protein expression and MAGE-A10 mRNA expression in the primary sites was 81.7% (P<0.0001).
  • The results of this study suggest that MAGE-A10 is a possible target in active immunotherapy for advanced stomach cancer.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Neoplasm Proteins / biosynthesis. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / chemistry. Disease Progression. Female. Gene Expression. Humans. Immunohistochemistry. In Situ Hybridization. Male. Melanoma-Specific Antigens. Middle Aged. RNA Probes. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. alpha-Fetoproteins / biosynthesis

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2004 Feb 23;90(4):838-43 [14970862.001]
  • [Cites] Mod Pathol. 2004 Feb;17(2):222-9 [14657947.001]
  • [Cites] Immunogenetics. 1994;40(5):360-9 [7927540.001]
  • [Cites] Gastroenterology. 1995 Nov;109(5):1522-5 [7557134.001]
  • [Cites] J Surg Oncol. 1997 Mar;64(3):195-201 [9121149.001]
  • [Cites] Anticancer Res. 1997 Sep-Oct;17(5A):3559-63 [9413202.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):449-61 [9790335.001]
  • [Cites] J Immunol. 1999 Jun 1;162(11):6849-54 [10352307.001]
  • [Cites] Oncol Rep. 1999 Sep-Oct;6(5):975-7 [10425289.001]
  • [Cites] Int J Cancer. 1999 Sep 9;82(6):901-7 [10446460.001]
  • [Cites] Cancer Immun. 2004 Nov 1;4:11 [15516106.001]
  • [Cites] Ann Surg. 2005 Jan;241(1):27-39 [15621988.001]
  • [Cites] J Immunol. 2005 Feb 1;174(3):1709-16 [15661935.001]
  • [Cites] Cancer Lett. 2005 Mar 10;219(2):223-32 [15723723.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):3080-6 [15728523.001]
  • [Cites] Postgrad Med J. 2005 Jul;81(957):419-24 [15998815.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3B):2105-11 [16158951.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8055-62 [16299236.001]
  • [Cites] Ann Surg. 2006 Feb;243(2):189-95 [16432351.001]
  • [Cites] Int J Oncol. 2006 May;28(5):1089-98 [16596224.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4693-700 [16651421.001]
  • [Cites] Pathol Int. 2006 Sep;56(9):510-5 [16930331.001]
  • [Cites] J Immunother. 2006 Sep-Oct;29(5):499-511 [16971806.001]
  • [Cites] Int J Cancer. 2007 Jan 15;120(2):337-43 [17066423.001]
  • [Cites] J Invest Dermatol. 2007 Feb;127(2):267-75 [16960553.001]
  • [Cites] Cancer Immunol Immunother. 2007 Jun;56(6):839-47 [16960690.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4355-9 [17671116.001]
  • [Cites] Arch Histol Cytol. 2007 Jul;70(2):127-34 [17827670.001]
  • [Cites] Int J Cancer. 2000 Jun 1;86(5):749-51 [10797302.001]
  • [Cites] Oncology. 2000 Aug;59(2):145-51 [10971174.001]
  • [Cites] Oncogene. 2001 Feb 15;20(7):869-73 [11314020.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5850-6 [11479225.001]
  • [Cites] J Clin Invest. 2002 Dec;110(12):1813-22 [12488431.001]
  • [Cites] Oncology. 2003;65(2):95-101 [12931013.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5601-6 [14500401.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):808-16 [15492562.001]
  • (PMID = 18594524.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / MAGE-A10 antigen; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / RNA Probes; 0 / RNA, Messenger; 0 / alpha-Fetoproteins
  • [Other-IDs] NLM/ PMC2480964
  •  go-up   go-down


54. Winter WE 3rd, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, Rubin SC, Muggia F, McGuire WP, Gynecologic Oncology Group: Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol; 2008 Jan 1;26(1):83-9
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
  • PURPOSE: To identify factors predictive of poor prognosis in a similarly treated population of women with stage IV epithelial ovarian cancer (EOC).
  • PATIENTS AND METHODS: A retrospective review of 360 patients with International Federation of Gynecology and Obstetrics stage IV EOC who underwent primary surgery followed by six cycles of intravenous platinum/paclitaxel was performed.
  • RESULTS: The median PFS and OS for this group of stage IV ovarian cancer patients was 12 and 29 months, respectively.
  • Multivariate regression analysis revealed that histology, malignant pleural effusion, intraparenchymal liver metastasis, and residual tumor size were significant prognostic variables.
  • Patients with less than 5.0 cm of disease initially and significant disease and/or comorbidities precluding microscopic cytoreduction may be considered for alternative therapeutic options other than primary cytoreduction.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Cisplatin / administration & dosage. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Female. Follow-Up Studies. Humans. Medical Records. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Pleural Effusion, Malignant / etiology. Postoperative Complications / etiology. Prognosis. Randomized Controlled Trials as Topic. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2008 Apr 1;26(10):1771-2; author reply 1772 [18375912.001]
  • (PMID = 18025437.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


55. Ferhi K, Lakehal M, Avakian R, Bensallah K, Boudjema K, Patard JJ, Guille F: [Combined liver-kidney transplantation: indications and results]. Prog Urol; 2008 Apr;18(4):245-50
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined liver-kidney transplantation: indications and results].
  • PURPOSE: The purpose of this article is to report our experience concerning the indications and results for combined liver-kidney transplantation in our centre.
  • MATERIAL AND METHOD: From July 1991 to October 2006, 26 patients underwent combined liver-kidney transplantation in our establishment.
  • The main indications were as follows: hepatorenal polycystic disease, type I hyperoxaluria, cirrhosis associated with end-stage renal failure.
  • Only two patients of this series died, one at 70 months from gastric cancer, and the other at 89 months from cerebral metastases.
  • Liver function was normal in the 24 surviving patients.
  • CONCLUSION: Combined liver-kidney transplantation can be performed with acceptable morbidity and mortality and excellent long-term results.
  • [MeSH-major] Kidney Transplantation. Liver Transplantation
  • [MeSH-minor] Adult. Aged. Cysts / complications. Cysts / surgery. Female. Follow-Up Studies. Humans. Hyperoxaluria, Primary / complications. Hyperoxaluria, Primary / surgery. Kidney Failure, Chronic / complications. Kidney Failure, Chronic / surgery. Liver Cirrhosis / complications. Liver Cirrhosis / surgery. Liver Diseases / complications. Liver Diseases / surgery. Male. Middle Aged. Polycystic Kidney Diseases / complications. Polycystic Kidney Diseases / surgery. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18501305.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


56. Agarwala A, Fisher W, Bruetman D, McClean J, Taber D, Titzer M, Juliar B, Yu M, Breen T, Einhorn LH, Hanna N: Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group. J Thorac Oncol; 2008 Apr;3(4):374-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group.
  • BACKGROUND: Gefitinib, an inhibitor of the epidermal growth factor receptor (EGFR) pathway, has single agent activity in non-small cell lung cancer (NSCLC).
  • METHODS: chemotherapy-naive, stage IIIb (with pleural effusion) or IV NSCLC, Eastern Cooperative Oncology Group Performance Status (PS) 0-1.
  • The primary objective was to evaluate the overall response rate; secondary objectives included estimation of progression free survival, overall survival, and to assess the toxicity of this regimen.
  • RESULTS: From January 2004 to November 2004, 31 patients were enrolled: male/female 13/18; median age 70 years (range, 19-93); 68% had adenocarcinoma; Eastern Cooperative Oncology Group PS 0/1 13/18; stage IIIb/IV 2/29.
  • Two additional patients discontinued treatment due to adverse events (elevated liver enzymes).
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Celecoxib. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Pyrazoles / administration & dosage. Quinazolines / administration & dosage. Sulfonamides / administration & dosage. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379355.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pyrazoles; 0 / Quinazolines; 0 / Sulfonamides; JCX84Q7J1L / Celecoxib; S65743JHBS / gefitinib
  •  go-up   go-down


57. Liu XB, Yuan ZY, Song YC, Li FT, Dong Y, Wang JS, Li XY, Wang P: [An initial report of cyberknife radiosurgery for primary hepatic carcinoma]. Zhonghua Zhong Liu Za Zhi; 2010 Mar;32(3):229-33
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An initial report of cyberknife radiosurgery for primary hepatic carcinoma].
  • OBJECTIVE: To study the efficacy and toxicity of cyberknife radiosurgery for primary hepatic carcinoma.
  • METHODS: From September 2006 to March 2008, 17 patients with clinical stage I-III primary hepatic carcinoma were treated with cyberknife at Tianjin Cancer Hospital.
  • Totally 23 lesions in the liver were treatment.
  • All the lesions in liver treated by the cyberknife radiosurgery achieved local control.
  • CONCLUSION: The cyberknife radiosurgery for primary hepatic carcinoma showed a high rate of local control and minimal toxicity.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Radiosurgery / methods
  • [MeSH-minor] Adult. Aged. Female. Fiducial Markers. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Remission Induction. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450595.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


58. Otsuka S, Inagaki M, Nishie M, Hamano R, Tokunaga N, Takahashi K, Tsunemitsu Y, Miyoshi K, Iwakawa K, Takahashi M, Iwagak H: [A case of pathological complete response of metachronous multiple liver metastases from colorectal cancer after mFOLFOX+bevacizumab chemotherapy]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2166-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of pathological complete response of metachronous multiple liver metastases from colorectal cancer after mFOLFOX+bevacizumab chemotherapy].
  • A 25-year-old man with RS rectal cancer received a radical resection of the original tumor and lymph node dissection.
  • Oral tegafur/uracil (UFT)/Leucovorin (LV) therapy has been used for adjuvant chemotherapy, as the pathological Stage was T3N1M0, Stage IIIa.
  • After 10 months from operation, multiple liver metastases were recognized and not resectable.
  • After 5 courses of mFOLFOX6+bevacizumab, abdominal CT revealed liver metastases showed remarkable reduction in size.
  • Pathological findings of S6 segment revealed no residual cancer cells, indicating the histological effect of mFOLFOX6+bevacizumab was Grade 3.
  • And no liver damage was recognized.
  • [MeSH-major] Angiogenesis Inhibitors / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Colorectal Neoplasms / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / secondary
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Bevacizumab. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Organoplatinum Compounds / administration & dosage

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037358.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Organoplatinum Compounds; 2S9ZZM9Q9V / Bevacizumab; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


59. Umeda T, Abe H, Kurumi Y, Naka S, Shiomi H, Hanasawa K, Morikawa S, Tani T: Magnetic resonance-guided percutaneous microwave coagulation therapy for liver metastases of breast cancer in a case. Breast Cancer; 2005;12(4):317-21
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance-guided percutaneous microwave coagulation therapy for liver metastases of breast cancer in a case.
  • Real-time magnetic resonance (MR) imaging enables the application of percutaneous microwave coagulation for high-risk patients with metastatic liver tumours.
  • MR-guided percutaneous microwave coagulation therapy is effective for treatment of not only primary liver tumours but also metastatic breast cancers in the liver, which are not diffuse but discrete, and difficult to treat with only chemo-and endocrine therapy.
  • We report a 44-year-old Japanese woman who underwent modified radical mastectomy for right breast cancer (T1c N0 M0 Stage I).
  • Three years after the operation, she developed two metastatic liver tumours and was treated by MR-guided percutaneous microwave coagulation, achieving a complete response (CR) without any recurrence for 15 months as of the present.
  • Additional clinical trials will be valuable to delineate the effectiveness and safety of MR-guided percutaneous microwave coagulation therapy for controlling the liver metastases of breast cancer.
  • [MeSH-major] Breast Neoplasms / pathology. Electrocoagulation / methods. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Microwaves / therapeutic use
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Humans. Magnetic Resonance Imaging. Mastectomy, Modified Radical. Treatment Outcome

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16286913.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


60. Rochet N, Jensen AD, Sterzing F, Munter MW, Eichbaum MH, Schneeweiss A, Sohn C, Debus J, Harms W: Adjuvant whole abdominal intensity modulated radiotherapy (IMRT) for high risk stage FIGO III patients with ovarian cancer (OVAR-IMRT-01) - Pilot trial of a phase I/II study: study protocol. BMC Cancer; 2007 Dec 19;7:227
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant whole abdominal intensity modulated radiotherapy (IMRT) for high risk stage FIGO III patients with ovarian cancer (OVAR-IMRT-01) - Pilot trial of a phase I/II study: study protocol.
  • BACKGROUND: The prognosis for patients with advanced epithelial ovarian cancer remains poor despite aggressive surgical resection and platinum-based chemotherapy.
  • Despite the clinically proven efficacy of whole abdominal irradiation, the use of radiotherapy in ovarian cancer has profoundly decreased mainly due to high treatment-related toxicity.
  • Modern intensity-modulated radiation therapy (IMRT) could allow to spare kidneys, liver, and bone marrow while still adequately covering the peritoneal cavity with a homogenous dose.
  • Patients with advanced ovarian cancer stage FIGO III (R1 or R2< 1 cm) after surgical resection and platinum-based chemotherapy will be treated with whole abdomen irradiation as consolidation therapy using intensity modulated radiation therapy (IMRT) to a total dose of 30 Gy in 1.5 Gy fractions.
  • For treatment planning bone marrow, kidneys, liver, spinal cord, vertebral bodies and pelvic bones are defined as organs at risk.
  • DISCUSSION: The primary endpoint of the study is the evaluation of the feasibility of intensity-modulated WAI and the evaluation of the study protocol.
  • The aim is to explore the potential of IMRT as a new method for WAI to decrease the dose to kidneys, liver, bone marrow while covering the peritoneal cavity with a homogenous dose, and to implement whole abdominal intensity-modulated radiotherapy into the adjuvant multimodal treatment concept of advanced ovarian cancer FIGO stage III.
  • [MeSH-minor] Adult. Aged. Clinical Protocols. Dose Fractionation. Endpoint Determination. Feasibility Studies. Female. Humans. Middle Aged. Neoplasm Staging. Organ Specificity. Patient Selection. Pilot Projects. Radiation Injuries / prevention & control. Research Design. Risk

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 1999 Dec;53(3):213-8 [10660201.001]
  • [Cites] Int J Gynecol Cancer. 2005 May-Jun;15 Suppl 1:3-11 [15839952.001]
  • [Cites] Forum (Genova). 2000 Oct-Dec;10(4):335-52 [11535984.001]
  • [Cites] Front Radiat Ther Oncol. 2002;36:25-34 [11842752.001]
  • [Cites] Radiother Oncol. 2002 Feb;62(2):163-71 [11937243.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1330-7 [11955746.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):12-22 [12007936.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):278-89 [12183002.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):312-21 [12527043.001]
  • [Cites] Radiother Oncol. 2003 Mar;66(3):313-21 [12742271.001]
  • [Cites] Int J Gynecol Cancer. 2003 May-Jun;13(3):278-86 [12801256.001]
  • [Cites] Radiologe. 2003 Jun;43(6):448-54 [12827259.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):516-21 [12957265.001]
  • [Cites] Strahlenther Onkol. 2003 Aug;179(8):535-41 [14509952.001]
  • [Cites] Br J Radiol. 2003 Oct;76(910):673 [14512325.001]
  • [Cites] Am J Clin Oncol. 2003 Oct;26(5):e136-43 [14528088.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):1019-32 [14575833.001]
  • [Cites] Acta Oncol. 2003;42(5-6):562-6 [14596514.001]
  • [Cites] Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:241-50 [14656286.001]
  • [Cites] Int J Gynaecol Obstet. 2003 Oct;83 Suppl 1:135-66 [14763172.001]
  • [Cites] JAMA. 2004 Jun 9;291(22):2755-6 [15187058.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 May;8(5):893-7 [7107423.001]
  • [Cites] Cancer. 1985 May 1;55(9 Suppl):2285-90 [3919934.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Sep;17(3):607-13 [2777649.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Nov;19(5):1203-6 [2254113.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1990 Jan;2(1):4-9 [2261388.001]
  • [Cites] Gynecol Oncol. 1991 Apr;41(1):30-5 [2026356.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(5):835-45 [1555974.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(5):847-51 [1555975.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(5):853-8 [1555976.001]
  • [Cites] Cancer. 1993 Feb 15;71(4 Suppl):1710-8 [8431909.001]
  • [Cites] Radiother Oncol. 1993 Jan;26(1):26-32 [8438083.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 8:viii36-viii38 [16239235.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 8:viii7-viii12 [16239238.001]
  • [Cites] N Engl J Med. 2006 Apr 13;354(15):1641-3; author reply 1641-3 [16611959.001]
  • [Cites] Radiother Oncol. 2006 Mar;78(3):276-82 [16546279.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2 Suppl 6):S3-11 [16716797.001]
  • [Cites] J Natl Compr Canc Netw. 2006 Oct;4(9):912-39 [17020669.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):783-92 [17070570.001]
  • [Cites] Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S161-92 [17161157.001]
  • [Cites] Recent Results Cancer Res. 2007;174:91-100 [17302189.001]
  • [Cites] Gynecol Oncol. 1993 Oct;51(1):97-103 [8244182.001]
  • [Cites] Semin Oncol. 1995 Jun;22(3 Suppl 6):78-83 [7541158.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):543-9 [9635700.001]
  • [Cites] Gynecol Oncol. 1999 Feb;72(2):215-9 [10021304.001]
  • [Cites] Cancer Invest. 2004;22 Suppl 2:11-20 [15573741.001]
  • [Cites] Cancer Invest. 2004;22(5):815-7 [15581063.001]
  • [Cites] Gynecol Oncol. 2005 Feb;96(2):389-94 [15661226.001]
  • [Cites] Br J Radiol. 2000 May;73(869):459-69 [10884741.001]
  • (PMID = 18093313.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2212657
  •  go-up   go-down


61. Katz KA, Jonasch E, Hodi FS, Soiffer R, Kwitkiwski K, Sober AJ, Haluska FG: Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res; 2005 Feb;15(1):77-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute.
  • Melanoma may present metastatically without an identifiable primary lesion.
  • To further characterize the epidemiology of melanoma of unknown primary (MUP), we report our experience with a cohort of MUP patients.
  • We retrospectively reviewed patients seen at the Massachusetts General Hospital (MGH) and the Dana-Farber Cancer Institute (DFCI) between 1986 and 1996 with follow-up to 2002.
  • After adjusting for stage and age at diagnosis, there was some evidence that men survived longer than women [hazard ratio (HR)=0.55; 95% CI, 0.28, 1.09].
  • [MeSH-major] Melanoma / epidemiology. Neoplasms, Unknown Primary / epidemiology. Skin Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Neoplasms / secondary. Boston / epidemiology. Brain Neoplasms / secondary. Cohort Studies. Female. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15714125.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Review
  • [Publication-country] England
  • [Number-of-references] 26
  •  go-up   go-down


62. Lee YK, Park NH, Kim JW, Song YS, Kang SB, Lee HP: Characteristics of recurrence in adult-type granulosa cell tumor. Int J Gynecol Cancer; 2008 Jul-Aug;18(4):642-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of recurrence in adult-type granulosa cell tumor.
  • There were 35 cases showing adult-type GCT, which were available for evaluation.
  • Factors affecting the recurrence involved residual tumor and stage, but residual tumor was the only significant factor of recurrence in multivariate analysis.
  • The median time to relapse was 75 months (range, 55-137 months), and the liver was the most common extra-pelvic metastatic site followed by the intestine.
  • Active management including complete tumorectomy is the most important treatment modality in both primary surgeries and recurrent cases.
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Metastasis. Prognosis. Recurrence. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17868338.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Nanashima A, Sumida Y, Abo T, Tobinaga S, Takeshita H, Hidaka S, Yasutake T, Nagayasu T, Mine M, Sawai T: A modified grading system for post-hepatectomy metastatic liver cancer originating from colorectal carcinoma. J Surg Oncol; 2008 Oct 1;98(5):363-70
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A modified grading system for post-hepatectomy metastatic liver cancer originating from colorectal carcinoma.
  • BACKGROUND AND OBJECTIVES: There is no appropriate grading system for prediction of survival of patients with metastatic liver cancer (MLC) from colorectal carcinoma.
  • METHODS: We compared predictive accuracies of survival of 121 Japanese MLC patients of five systems, including clinical risk score (CRS) proposed by Memorial-Sloan-Kettering-Cancer-Center, original H-number (OHN) by Japanese Society for Cancer of the Colon and Rectum, revised H-number (RHN) and Grade by the same society (GJSCCR), and our modified Grade (MGJSCCR) based on OHN and presence of primary lymph node metastasis.
  • Multivariate analysis showed CRS and MGJSCCR as the best systems for predicting disease-free and overall survival according to disease stage, for which Akaike information criteria (AIC) value was the lowest (423.7 and 313.9, hazard ratio 1.73 and 1.47, respectively for CRS, 423.9 and 313.5, hazard ratio 1.75 and 1.69, respectively for MGJSCCR; P < 0.05).
  • [MeSH-major] Colorectal Neoplasms / pathology. Liver Neoplasms / pathology. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Hepatectomy. Humans. Japan. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests. Survival Analysis. Survival Rate


64. Wu F, Wu L, Zheng S, Ding W, Teng L, Wang Z, Ma Z, Zhao W: The clinical value of hepatocyte growth factor and its receptor--c-met for liver cancer patients with hepatectomy. Dig Liver Dis; 2006 Jul;38(7):490-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical value of hepatocyte growth factor and its receptor--c-met for liver cancer patients with hepatectomy.
  • BACKGROUND: To study the dynamic change of hepatocyte growth factor after hepatectomy in patients with primary liver cancer, and to analyse the prognostic value of hepatocyte growth factor and c-met for these patients.
  • METHODS: Thirty-one consecutive patients undergoing partial hepatectomy for liver cancer were studied.
  • RESULTS: Liver cancer patients had a significantly higher level of serum hepatocyte growth factor than normal controls (1.0424+/-0.498 ng/ml versus 0.685+/-0.115 ng/ml, p=0.008).
  • CONCLUSION: The over-expressions of the hepatocyte growth factor and c-met indicates an adverse prognosis for patients with liver cancer.
  • Liver regeneration may be a main factor leading to high level of serum hepatocyte growth factor in early postoperative stage.
  • [MeSH-major] Biomarkers, Tumor / blood. Biomarkers, Tumor / metabolism. Hepatectomy. Hepatocyte Growth Factor / blood. Liver Neoplasms / diagnosis. Liver Neoplasms / metabolism. Proto-Oncogene Proteins c-met / metabolism
  • [MeSH-minor] Adult. Aged. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. RNA, Messenger / genetics

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16627020.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 67256-21-7 / Hepatocyte Growth Factor; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  •  go-up   go-down


65. Lao XM, Chen DY, Zhang YQ, Xiang J, Guo RP, Lin XJ, Li JQ: Primary carcinosarcoma of the liver: clinicopathologic features of 5 cases and a review of the literature. Am J Surg Pathol; 2007 Jun;31(6):817-26
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary carcinosarcoma of the liver: clinicopathologic features of 5 cases and a review of the literature.
  • Carcinosarcoma of the liver is very rare worldwide.
  • Radical resection of early stage hepatic carcinosarcoma may contribute to a relatively optimistic prognosis.
  • [MeSH-major] Carcinosarcoma / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17527068.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Modanlou KA, Oliver DA, Grossman BJ: Liver donor's age and recipient's serum creatinine predict blood component use during liver transplantation. Transfusion; 2009 Dec;49(12):2645-51
MedlinePlus Health Information. consumer health - Organ Donation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver donor's age and recipient's serum creatinine predict blood component use during liver transplantation.
  • BACKGROUND: Excessive use of blood components during liver transplantation should be avoided because it has been associated with poor outcomes and it may stress blood bank resources.
  • STUDY DESIGN AND METHODS: To determine preoperative predictors of excessive transfusion requirements in patients undergoing liver transplantation, the clinical records of 126 consecutive adult patients undergoing primary liver transplantation were retrospectively reviewed.
  • Univariate analyses of the following predictor variables were performed: recipient age, sex, ethnicity, height/weight, Model for End Stage Liver Disease score, year of transplant, previous abdominal surgery, hepatoma, wait-list time, standard recipient laboratory values obtained immediately before transplantation, cold ischemia time, donor age, sex, and height/weight.
  • ] CONCLUSION: Liver donor's age and recipient's SCr are important in preoperatively predicting blood use during liver transplantation.
  • [MeSH-major] Blood Component Transfusion. Blood Loss, Surgical / prevention & control. Creatinine / blood. Liver Transplantation. Tissue Donors
  • [MeSH-minor] Adult. Age Factors. Aged. Blood Banks. Erythrocyte Count. Female. Humans. Logistic Models. Male. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Preoperative Care. Retrospective Studies

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Creatinine.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19682344.001).
  • [ISSN] 1537-2995
  • [Journal-full-title] Transfusion
  • [ISO-abbreviation] Transfusion
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] AYI8EX34EU / Creatinine
  •  go-up   go-down


67. Irimie A, Achimas-Cadariu P, Burz C, Puscas E: Multiple primary malignancies--epidemiological analysis at a single tertiary institution. J Gastrointestin Liver Dis; 2010 Mar;19(1):69-73

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple primary malignancies--epidemiological analysis at a single tertiary institution.
  • BACKGROUND: A literature review on 1,104 269 cancer patients concluded that the prevalence of multiple primary malignancies (MPM) is between 0.73% and 11.7%.
  • AIM: The purpose of this study was to investigate clinically useful information for effective screening for synchronous and metachronous second primary cancers and to identify a potential surveillance protocol.
  • Both primary and secondary tumors tended to be in an advanced stage explained by the low compliance of the patients to follow-up.
  • Screening procedures are especially useful for the early detection of associated tumors, whereas careful monitoring of patients treated for primary cancer and a good communication between patients and medical care team would ensure an early detection for secondary tumors, and, subsequently, an appropriate management.
  • [MeSH-major] Neoplasms, Multiple Primary / epidemiology. Neoplasms, Second Primary / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Early Detection of Cancer. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Romania / epidemiology. Time Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20361078.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


68. Peng SY, Lai PL, Pan HW, Hsiao LP, Hsu HC: Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis. Oncol Rep; 2008 Apr;19(4):1045-53
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis.
  • Cancer cells with a high glycolytic rate have an advantage in tumor growth.
  • HKII mRNA was overexpressed in 70 (35%) primary HCCs.
  • The ALDOB down-regulation and HKII overexpression correlated with high-grade (grade II-IV) HCC (all ps<0.0001), portal vein invasion (stage IIIB-IV) (ps<1x10(-6)), early tumor recurrence (ETR) (p<0.001 and p<0.01, respectively) and a lower 5-year survival (p=0.000001 and p=0.0062, respectively).
  • Notably, in stage II HCC which had no vascular invasion, the ALDOB down-regulation was associated with ETR (p<0.05) and a lower 5-year survival (p=0.015).
  • In conclusion, the aberrant expression of ALDOB and HKII is associated with advanced disease, ETR and poor prognosis, and ALDOB down-regulation in stage II HCC is a predictive marker of ETR and an unfavorable outcome.
  • [MeSH-major] Carcinoma, Hepatocellular / enzymology. Fructose-Bisphosphate Aldolase / genetics. Hexokinase / genetics. Liver Neoplasms / enzymology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Gene Expression Regulation, Enzymologic. Genes, p53. Humans. Male. Middle Aged. Mutation. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. RNA, Messenger / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18357395.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.1.1 / Hexokinase; EC 4.1.2.13 / Fructose-Bisphosphate Aldolase
  •  go-up   go-down


69. Schiel KA: An etiologic model proposing that sporadic adult-onset carcinoma is extramedullary hematopoiesis. Med Hypotheses; 2006;67(1):93-109
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An etiologic model proposing that sporadic adult-onset carcinoma is extramedullary hematopoiesis.
  • This model proposes that primary carcinomatous tumors and almost all metastases are extramedullary hematopoietic tissue formed to compensate for reduced hematopoietic activity in the bone marrow.
  • Specific carcinoma morphologies are equated to stages in endochondral bone and marrow formation and, as such, cancer cell identity varies with morphology.
  • This morphology is equated to the cartilagenous stage of marrow formation, when mesenchymal stem cells proliferate and differentiate into chondroblasts.
  • Tubular breast carcinoma, with its single layer of osteoblast-like carcinoma cells encircling small lumens and long branching tubules, is equated to the trabecular stage of marrow formation during which osteoblasts surround small pieces of calcified cartilage and begin secreting osteoid that will form the trabeculae.
  • Lobular carcinoma in situ consists of cancer cell clusters separated by narrow clear spaces that, under high magnification, appear vascular.
  • If cancer cells are not the enemy, but desperately needed immature blood cells, and the medical problem is not the presence of tumors, but the inefficiency of this extramedullary hematopoietic tissue, then treatment should focus on increasing marrow hematopoiesis.
  • [MeSH-major] Carcinoma / etiology. Hematopoiesis, Extramedullary. Liver Neoplasms / etiology
  • [MeSH-minor] Adult. Bone Marrow Cells. Granulocytes / metabolism. Hematopoietic Stem Cells / cytology. Humans. Leukemia / metabolism. Models, Biological. Neoplasm Metastasis. Primary Myelofibrosis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540257.001).
  • [ISSN] 0306-9877
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


70. Yan K, Wang YB, Chen MH, Gao W, Yang W, Dai Y, Yin SS: [Prognostic factors on outcome of radiofrequency ablation of 172 primary hepatic tumors]. Zhonghua Yi Xue Za Zhi; 2005 Aug 31;85(33):2322-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors on outcome of radiofrequency ablation of 172 primary hepatic tumors].
  • OBJECTIVE: To investigate the prognostic factors affecting outcome in Radiofrequency (RF) ablation of primary hepatic tumors by univariate and multivariate analyses, and to assess the therapeutic efficacy of Radio-frequency ablation.
  • METHODS: A total of 172 patients with primary hepatic tumors underwent RF treatment in our department between 1999 and 2004.
  • These 8 factors were Child-Pugh grade, UICC stage, AFP value before first RF, Portal hypertension, first treatment or treatment for recurrence, pathological grade, treatment purpose and method, ablative safe margin.
  • For 116 patients who underwent RF when first diagnosis, the survival rates in patients with different tumor stage (UICC standard of hepatocellular carcinoma) at half a year, 1 year, 2 year and 3 year were estimated as follows: 96.7%, 92.3%, 81.6% and 65.3% in 33 patients of stage I-II; 91.2%, 76.3%, 56.6% and 51.4% in 83 patients of stage III-IV; There was significant difference in survival rates between patients of stage I-II and patients of stage III-IV.
  • For 56 patients suffered from recurrent hepatic tumors, the survival rates at half a year, 1 year, 2 year and 3 year were 88.5%, 70.2%, 41.4% and 24.5%, being similar to those of stage III-IV.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Multivariate Analysis. Prognosis. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321224.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


71. Quek ML, Nichols PW, Yamzon J, Daneshmand S, Miranda G, Cai J, Groshen S, Stein JP, Skinner DG: Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern california experience. J Urol; 2005 Jul;174(1):93-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern california experience.
  • PURPOSE: Primary neuroendocrine tumors of the bladder are rare and they include small and large cell variants.
  • MATERIALS AND METHODS: From August 1971 to June 2004, 2,005 patients underwent radical cystectomy for primary bladder cancer at our institution, of whom 25 (1.2%) had neuroendocrine tumors of the bladder, including small cell carcinoma in 20 and large cell carcinoma in 5.
  • A total of 19 patients (76%) had lymph node involvement, of whom 2 had small liver metastases found intraoperatively, while only 4 (16%) had organ confined tumors and 2 (8%) had extravesical, node negative disease.
  • CONCLUSIONS: Neuroendocrine tumors of the bladder usually present with advanced pathological stage and portend a poor prognosis.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15947585.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Karoui M, Koubaa W, Delbaldo C, Charachon A, Laurent A, Piedbois P, Cherqui D, Tran Van Nhieu J: Chemotherapy has also an effect on primary tumor in colon carcinoma. Ann Surg Oncol; 2008 Dec;15(12):3440-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy has also an effect on primary tumor in colon carcinoma.
  • BACKGROUND: This study characterizes the histological effect of chemotherapy (CT) on primary colonic tumors.
  • METHODS: Between 2000 and 2006, 38 patients with stage IV colon cancer underwent resection of the primary, after chemotherapy (CT group, n = 16) or without preoperative CT (control group, n = 22).
  • For all primary tumors, histological analysis included: fibrosis, acellular necrosis, acellular mucin pools, lymphoplasmacytic infiltration, and changes at tumor surface.
  • TRG in the primary was comparable to the TRG in the corresponding liver metastases for 7/9 patients who underwent both colonic and hepatic resection after CT.
  • Response to CT in the primary and the corresponding liver metastases are correlated.
  • These results support a policy of initial CT management for stage IV colon cancer and may warrant future studies of neoadjuvant CT in locally advanced colon carcinomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology. Liver Neoplasms / drug therapy. Neoplasm, Residual / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Remission Induction. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18850249.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Frumovitz M, Etchepareborda M, Sun CC, Soliman PT, Eifel PJ, Levenback CF, Ramirez PT: Primary malignant melanoma of the vagina. Obstet Gynecol; 2010 Dec;116(6):1358-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant melanoma of the vagina.
  • METHODS: Thirty-seven women with clinical and radiographic stage I vaginal melanoma treated at one institution between 1980 and 2009 were included in this retrospective study.
  • Treatment modalities were assigned to one of three categories: pelvic exenteration, wide excision, and nonsurgical (primary radiation therapy, chemotherapy, or both).
  • The most common sites of distant recurrence were lungs and liver.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21099603.001).
  • [ISSN] 1873-233X
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Yuan RH, Jeng YM, Chen HL, Hsieh FJ, Yang CY, Lee PH, Hsu HC: Opposite roles of human pancreatitis-associated protein and REG1A expression in hepatocellular carcinoma: association of pancreatitis-associated protein expression with low-stage hepatocellular carcinoma, beta-catenin mutation, and favorable prognosis. Clin Cancer Res; 2005 Apr 1;11(7):2568-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Opposite roles of human pancreatitis-associated protein and REG1A expression in hepatocellular carcinoma: association of pancreatitis-associated protein expression with low-stage hepatocellular carcinoma, beta-catenin mutation, and favorable prognosis.
  • EXPERIMENTAL DESIGN: PAP and REG1A mRNA levels were measured in 265 surgically removed unifocal primary HCCs using reverse transcription-PCR.
  • HCCs with PAP expression correlated with low-stage tumors without evidence of vascular invasion (P = 0.013) but the REG1A expression did not.
  • By a combination analysis, HCCs with PAP expression alone showed the lowest frequency of p53 mutation (P < 0.036), the highest rates of grade 1 and low-stage tumors (P < 0.007 and P < 0.001, respectively), less frequent early tumor recurrence (P = 0.051), and hence a better 5-year survival (P = 0.044) than groups expressing PAP and REG1A, REG1A alone, and neither PAP or REG1A.
  • CONCLUSIONS: These data suggest that PAP expression designate a subset of low-grade, low-stage HCC with frequent beta-catenin mutation and hence more favorable prognosis, whereas further genetic or epigenetic alterations, such as p53 mutation and REG1A expression, lead to more advanced HCCs.
  • [MeSH-major] Antigens, Neoplasm / genetics. Biomarkers, Tumor / genetics. Calcium-Binding Proteins / genetics. Carcinoma, Hepatocellular / pathology. Lectins, C-Type / genetics. Liver Neoplasms / pathology. Nerve Tissue Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cytoskeletal Proteins / genetics. Disease Progression. Female. Gene Expression Regulation, Neoplastic / physiology. Humans. Lithostathine. Male. Middle Aged. Mutation. Neoplasm Staging. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Survival Analysis. Trans-Activators / genetics. Tumor Suppressor Protein p53 / genetics. beta Catenin

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15814635.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / Calcium-Binding Proteins; 0 / Cytoskeletal Proteins; 0 / Lectins, C-Type; 0 / Lithostathine; 0 / Nerve Tissue Proteins; 0 / REG1A protein, human; 0 / RNA, Messenger; 0 / Trans-Activators; 0 / Tumor Suppressor Protein p53; 0 / beta Catenin; 0 / pancreatitis-associated protein
  •  go-up   go-down


75. Agrawal S, McCarron EC, Gibbs JF, Nava HR, Wilding GE, Rajput A: Surgical management and outcome in primary adenocarcinoma of the small bowel. Ann Surg Oncol; 2007 Aug;14(8):2263-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management and outcome in primary adenocarcinoma of the small bowel.
  • BACKGROUND: Primary adenocarcinoma of the small bowel is a rare malignancy and is associated with poor survival outcome.
  • METHODS: Between 1971 and 2005, 64 patients with primary adenocarcinoma of the small bowel were treated at our institution.
  • The most common sites of recurrence following a curative resection were the liver and lung.
  • On multivariate analysis, absence of distant metastatic disease (5-year survival 30.4%), curative resection (5-year survival 44.8%) and pathological T stage 1-3 (5-year survival 39.2%) were identified as independent predictors of survival.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Survival Rate. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549572.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Pan Z, Zhang H, Yan C, Du L, Ding B, Song Q, Ling H, Huang B, Chen K: Determining gastric cancer resectability by dynamic MDCT. Eur Radiol; 2010 Mar;20(3):613-20
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determining gastric cancer resectability by dynamic MDCT.
  • PURPOSE: Multi-detector row CT (MDCT) has been widely used to detect primary lesions and to evaluate TNM staging.
  • In this study we evaluated the accuracy of dynamic MDCT in the preoperative determination of the resectability of gastric cancer.
  • METHODS: MDCT was used to image 350 cases of gastric cancer diagnosed by biopsy before surgery.
  • RESULTS: The accuracy of MDCT for staging gastric cancer was high, especially for tumour stage T1 (94.3%), lymph node stage N2 (87.3%), and for predicting distant metastases (>96.6%).
  • Results showed high sensitivity for identifying peritoneal seeding (90.0%) and for predicting liver metastasis (80.0%).
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Prognosis. Reproducibility of Results. Sensitivity and Specificity. Treatment Outcome

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19707768.001).
  • [ISSN] 1432-1084
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


77. Bock O, Neuse J, Hussein K, Brakensiek K, Buesche G, Buhr T, Wiese B, Kreipe H: Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status. Am J Pathol; 2006 Aug;169(2):471-81
Genetic Alliance. consumer health - Myelofibrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status.
  • Whereas no correlation was found between the JAK2 status and MMP gene products, there was an evident association with the stage of disease.
  • We conclude that the expression of matrix-modeling genes in cIMF is not influenced by the JAK2 mutation status but is predominantly related to the stage of disease.
  • [MeSH-major] Collagenases / genetics. Mutation / genetics. Primary Myelofibrosis / enzymology. Primary Myelofibrosis / genetics. Protein-Tyrosine Kinases / genetics. Proto-Oncogene Proteins / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Marrow Cells / enzymology. Disease Progression. Endothelial Cells / enzymology. Endothelial Cells / pathology. Female. Fibrosis / pathology. Hematopoiesis / genetics. Humans. Janus Kinase 2. Male. Matrix Metalloproteinases / genetics. Megakaryocytes / enzymology. Megakaryocytes / pathology. Middle Aged. Protein Transport. RNA, Messenger / genetics. RNA, Messenger / metabolism. Tissue Inhibitor of Metalloproteinases / genetics. Up-Regulation / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mol Diagn. 2006 May;8(2):170-7 [16645202.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):248-58 [16397238.001]
  • [Cites] Blood. 2000 Nov 15;96(10):3374-80 [11071630.001]
  • [Cites] J Immunol. 2001 Mar 1;166(5):3491-8 [11207308.001]
  • [Cites] Anal Biochem. 2001 Aug 1;295(1):116-7 [11476553.001]
  • [Cites] Br J Haematol. 2001 Oct;115(1):195-204 [11722433.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Methods. 2001 Dec;25(4):409-18 [11846610.001]
  • [Cites] Br J Haematol. 2002 Dec;119(3):709-12 [12437648.001]
  • [Cites] Am J Clin Pathol. 2003 Jan;119(1):152-8 [12520711.001]
  • [Cites] Circ Res. 2003 May 2;92(8):827-39 [12730128.001]
  • [Cites] J Pathol. 2003 Jul;200(4):448-64 [12845612.001]
  • [Cites] Eur J Haematol. 2003 Oct;71(4):276-82 [12950237.001]
  • [Cites] Acta Haematol. 2004;111(3):155-9 [15034237.001]
  • [Cites] Cell Adhes Commun. 1993 Sep;1(2):93-9 [8081879.001]
  • [Cites] Cell. 1998 Feb 6;92(3):391-400 [9476898.001]
  • [Cites] Blood. 1998 Dec 15;92(12):4641-51 [9845530.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2627-36 [10194442.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Dec;287(6):G1227-37 [15284024.001]
  • [Cites] J Cell Biol. 2004 Nov 22;167(4):757-67 [15545316.001]
  • [Cites] Lancet. 2005 Mar 19-25;365(9464):1054-61 [15781101.001]
  • [Cites] J Pathol. 2005 Apr;205(5):548-57 [15726648.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):387-97 [15837627.001]
  • [Cites] N Engl J Med. 2005 Apr 28;352(17):1779-90 [15858187.001]
  • [Cites] Nature. 2005 Apr 28;434(7037):1144-8 [15793561.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4508-15 [15705794.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4187-90 [15817681.001]
  • [Cites] Br J Haematol. 2005 Jul;130(1):76-82 [15982347.001]
  • [Cites] Haematologica. 2005 Aug;90(8):1128-32 [16079113.001]
  • [Cites] Leuk Lymphoma. 2005 Sep;46(9):1261-8 [16109602.001]
  • [Cites] J Exp Med. 2005 Sep 5;202(5):663-71 [16147977.001]
  • [Cites] Semin Hematol. 2005 Oct;42(4):248-58 [16210038.001]
  • [Cites] FEBS Lett. 2005 Oct 24;579(25):5487-93 [16213498.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3370-3 [16037387.001]
  • [Cites] J Cell Physiol. 2006 Jan;206(1):1-8 [15920734.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8520-30 [16293880.001]
  • [Cites] Nat Cell Biol. 2000 Oct;2(10):737-44 [11025665.001]
  • (PMID = 16877349.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / Tissue Inhibitor of Metalloproteinases; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2; EC 3.4.24.- / Collagenases; EC 3.4.24.- / Matrix Metalloproteinases
  • [Other-IDs] NLM/ PMC1780160
  •  go-up   go-down


78. Artigas V, Marín-Hargreaves G, Marcuello E, Pey A, González JA, Rodríguez M, Moral A, Monill JM, Sancho J, Pericay C, Trias M: [Surgical resection of liver metastases from colorectal carcinoma. Experience in Sant Pau Hospital]. Cir Esp; 2007 Jun;81(6):339-44
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical resection of liver metastases from colorectal carcinoma. Experience in Sant Pau Hospital].
  • INTRODUCTION: Surgical resection is the only available treatment that improves survival in patients with liver metastases from colorectal cancer, particularly when carried out by a multidisciplinary team.
  • MATERIAL AND METHOD: We retrospectively analyzed a consecutive series of 116 patients who underwent 138 liver resections (65.4% minor and 35.5% major) for hepatic metastases from colorectal cancer between 1998 and 2004.
  • In 67.3% of the patients, the primary tumor was at an advanced stage (III-IV).
  • Survival rates varied according to whether the patients had < 4 or > or = 4 colorectal liver metastases (50 and 43 months respectively), tumor size (more or less than 5 cm) (60 and 50.6 months respectively) and whether the site was monolobar or bilobar (60 and 43.11 months respectively).
  • In 16 patients, recurrence of liver metastases led to 22 rehepatectomies.
  • CONCLUSIONS: These results confirm that multidisciplinary decisions and interventions by specialist liver surgeons, as in our hospital, reduce postoperative morbidity and mortality and increase survival in patients requiring surgical removal of liver metastases from colorectal cancer.
  • [MeSH-major] Colorectal Neoplasms / pathology. Colorectal Neoplasms / secondary. Colorectal Neoplasms / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hospitalization. Humans. Male. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17553407.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


79. Sviteková M, Minár L, Pacovský Z: [Breast cancer in puerperium]. Klin Onkol; 2008;21(2):71-3
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Breast cancer in puerperium].
  • CASE REPORT: Patient was 29 years old woman, without any familiar or personal history of cancer or cancer risk factors.
  • The core cut biopsy revealed invasive ductal carcinoma grade 3 and the staging was determinated as T4b N2 M1 (liver).
  • Because of the high clinical stage of the disease, primary sugical therapy (modified radical mastectomy) was not indicated and the patient underwent neoadjuvant chemotherapy followed byradiotherapy.
  • There was a control PET scan after the chemotherapy which confirmed only residual tumor in the area of affected breast and no viable tumor cells in the area of the liver.
  • Additional reduction of the primary tumor lesion occured after the radiotherapy.
  • [MeSH-minor] Adult. Female. Humans. Pregnancy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Postpartum Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19102215.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


80. Belda T, Montalvá EM, López-Andújar R, Rosell E, Moya A, Gómez I, Mir J: [Role of resection surgery in breast cancer liver metastases. Experience over the last 10 years in a reference hospital]. Cir Esp; 2010 Sep;88(3):167-73
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Role of resection surgery in breast cancer liver metastases. Experience over the last 10 years in a reference hospital].
  • INTRODUCTION: Breast cancer liver metastases (BCLM) are considered as a systemic disease which is mainly treated with chemotherapy, while the role of surgical resection still remains to be well defined.
  • The aim of the study is to analyse the survival and prognostic factors predictive of mortality in patients with BCLM treated by liver resection.
  • MATERIAL AND METHODS: A total of 21 patients were operated on between 1998-2008, with liver resection being performed on 12.
  • The most frequent stage was I, with curative surgery in all cases, and the majority (66.7%) received adjuvant treatment.
  • The liver resection was R0 in all cases with no morbidity and a mortality in the long term of 8.3%.
  • A disease free period of less than 24 months between the primary tumour and the appearance of metastasis was associated with a worse survival.
  • [MeSH-major] Breast Neoplasms / pathology. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Hospitals. Humans. Middle Aged. Prognosis. Retrospective Studies. Survival Rate. Time Factors

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 AEC. Published by Elsevier Espana. All rights reserved.
  • (PMID = 20638652.001).
  • [ISSN] 1578-147X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


81. Obed A, Tsui TY, Schnitzbauer AA, Obed M, Schlitt HJ, Becker H, Lorf T: Liver transplantation as curative approach for advanced hepatocellular carcinoma: is it justified? Langenbecks Arch Surg; 2008 Mar;393(2):141-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation as curative approach for advanced hepatocellular carcinoma: is it justified?
  • BACKGROUND: Liver transplantation is considered as one of therapeutic approaches to hepatocellular carcinoma (HCC).
  • Patients were treated either with primary tumour resection, transarterial chemoembolisation (TACE) or liver transplantation (LTx) by an interdisciplinary team.
  • RESULTS: The overall 1-year and 5-year survivals of patients in LTx group were 95 and 57%, respectively, which were significantly higher than those in primary tumour resection group (65 and 33%, P < 0.01) and those in TACE group (44 and 4%, P < 0.01).
  • In parallel, 1-year and 5-year tumour-free survivals of patients in LTx group (75 and 62%) were significantly higher than those in primary tumour resection group (50 and 11%, P < 0.01).
  • There were no significant differences in 1- and 5-year survivals of patients with early tumour stage received LTx or primary tumour resection, whereas patients in advanced tumour stage based on pathological findings of explanted liver significantly benefited from LTx as compared to primary resection.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 1999 Dec;30(6):1434-40 [10573522.001]
  • [Cites] Liver Transpl. 2006 Aug;12(8):1260-7 [16826556.001]
  • [Cites] Hepatology. 2001 May;33(5):1080-6 [11343235.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • [Cites] Liver Transpl. 2001 Oct;7(10):877-83 [11679986.001]
  • [Cites] Semin Oncol. 2001 Oct;28(5):474-86 [11685740.001]
  • [Cites] Ann Surg. 2002 May;235(5):722-30; discussion 730-1 [11981219.001]
  • [Cites] Hepatology. 2002 May;35(5):1164-71 [11981766.001]
  • [Cites] Ann Surg. 2003 Oct;238(4):508-18; discussion 518-9 [14530722.001]
  • [Cites] Liver Transpl. 2004 Feb;10(2 Suppl 1):S39-45 [14762838.001]
  • [Cites] Cancer. 2004 Aug 15;101(4):796-802 [15305412.001]
  • [Cites] Ann Surg. 1993 Aug;218(2):145-51 [8393649.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):693-9 [8594428.001]
  • [Cites] Gan To Kagaku Ryoho. 1997 May;24 Suppl 1:9-16 [9210883.001]
  • [Cites] Hepatology. 1998 Jun;27(6):1572-7 [9620329.001]
  • [Cites] Transpl Int. 1998;11 Suppl 1:S189-92 [9664976.001]
  • [Cites] J Hepatol. 1998 Jul;29(1):129-34 [9696501.001]
  • [Cites] J Hepatol. 1998 Dec;29(6):953-9 [9875642.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):324-31 [10458250.001]
  • [Cites] Am J Transplant. 2005 Apr;5(4 Pt 1):795-804 [15760404.001]
  • [Cites] Eur J Surg Oncol. 2005 May;31(4):331-47 [15837037.001]
  • [Cites] Transplantation. 2005 Sep 27;80(1 Suppl):S113-9 [16286887.001]
  • [Cites] Jpn J Clin Oncol. 2006 Apr;36(4):212-7 [16613896.001]
  • [Cites] Transplant Proc. 2006 May;38(4):1111-3 [16757280.001]
  • [Cites] Hepatology. 2000 Dec;32(6):1224-9 [11093728.001]
  • (PMID = 18043937.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC3085731
  •  go-up   go-down


82. Chen WJ, Kuo JY, Chen KK, Lin AT, Chang YH, Chang LS: Primary urothelial carcinoma of the ureter: 11-year experience in Taipei Veterans General Hospital. J Chin Med Assoc; 2005 Nov;68(11):522-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary urothelial carcinoma of the ureter: 11-year experience in Taipei Veterans General Hospital.
  • The aim of this study was to evaluate the clinical behavior, survival, recurrence and prognostic information of primary ureteral urothelial carcinoma from our 11 years of experience at the Taipei Veterans General Hospital.
  • Tumor staging was according to the 2002 AJCC TNM classification and stage groupings.
  • Patients with stage Oa and stage Ois were categorized as stage Oa/is, and patients with pathologic T stage pTa and pTis were categorized as pTa/is for statistical analysis.
  • Of the 111 patients, 5 presented with stage Oa/is, 38 with stage I, 23 with stage II, 21 with stage III, and 24 with stage IV.
  • Disease recurrence in the nephroureterectomy group occurred in 36 patients (46.2%), with 17 (21.8%) at the urinary bladder, 2 (2.6%) at the retroperitoneum, 1 (1.3%) at the contralateral ureter, 6 (7.7%) with distant metastases to the lung, bone, distant lymph nodes or liver, and 10 (12.8%) at multiple sites.
  • The 5-year cancer-specific survival rate was 100% for pTa/is, 95.2% for pT1, 69.4% for pT2, and 43.8% for pT3.
  • All 3 pT4 cases died of cancer in a median of 12 months.
  • Significant prognostic factors for cancer-specific survival by univariate analysis were pT (p = 0.00001), stage (p = 0.00001), type of treatment (p = 0.00001) and grade (p = 0.0001).
  • On multivariate analysis, only stage (p = 0.0001) and grade (p = 0.014) were significant for cancer-specific and overall survival.
  • Stage (p = 0.0001), pT (p =0.0001) and grade (p = 0.026) were also significant prognostic factors of recurrence in multivariate analysis.
  • Tumor stage and grade are the only significant prognostic factors for both cancer-specific and overall survival.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16323396.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


83. Sakai Y, Saotome T, Fujimori M, Shimizu S, Inkyo T, Yugeta H, Ohbu M, Koma Y, Sato T, Nagashima F, Hayasaka A, Fukuyama Y, Tsuchiya S, Tsuyuguchi T, Saisho H: [A pilot study of TS-1+CDDP therapy for highly advanced stage IV gastric cancer]. Gan To Kagaku Ryoho; 2005 Sep;32(9):1319-22
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A pilot study of TS-1+CDDP therapy for highly advanced stage IV gastric cancer].
  • We performed a pilot study of combination chemotherapy with TS-1 and cisplatin for highly advanced gastric cancer.
  • From June 2002, 12 patients with multiple liver metastases, carcinomatous lymphangitis or peritoneal dissemination, were enrolled in the study.
  • An objective response was obtained in 9 cases (75.0%) of primary sites and 6 cases of metastatic sites.
  • The TS-1/CDDP regimen had almost no survival benefits, but may induce relief of symptoms due to cancer and better quality of life.
  • [MeSH-minor] Administration, Oral. Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Drug Combinations. Female. Humans. Male. Middle Aged. Oxonic Acid / administration & dosage. Paclitaxel / administration & dosage. Pilot Projects. Pyridines / administration & dosage. Quality of Life. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16184932.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


84. Zhan XK, Sun YK, Zhang W, Wang JW: [Clinical analysis of 81 cases with primary small cell carcinoma of the esophagus]. Zhonghua Zhong Liu Za Zhi; 2008 Dec;30(12):926-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 81 cases with primary small cell carcinoma of the esophagus].
  • OBJECTIVE: To evaluate the clinical characteristics, treatment and prognostic factors in patients with primary small cell carcinoma (SmCC) of the esophagus.
  • RESULTS: Of the 81 patients, 52 (64.2%) were in limited stage (LS) and 23 (28.4%) in extensive stage (ES).
  • Multivariate analysis showed that disease stage, performance status, multidisciplinary comprehensive therapy and mode of treatment were independent prognostic factors.
  • Disease stage and performance status are important prognostic factors.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / therapeutic use. Combined Modality Therapy. Esophagectomy. Etoposide / therapeutic use. Female. Follow-Up Studies. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Neoplastic Cells, Circulating. Proportional Hazards Models. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173995.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; JET protocol
  •  go-up   go-down


85. Schmid P, Krocker J, Jehn C, Michniewicz K, Lehenbauer-Dehm S, Eggemann H, Heilmann V, Kümmel S, Schulz CO, Dieing A, Wischnewsky MB, Hauptmann S, Elling D, Possinger K, Flath B: Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial. Ann Oncol; 2005 Oct;16(10):1624-31
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial.
  • BACKGROUND: Combinations of anthracyclines, taxanes and gemcitabine have shown high activity in breast cancer.
  • This trial was designed to evaluate a modified combination regimen as primary chemotherapy.
  • PATIENTS AND METHODS: Forty-four patients with histologically confirmed stage II or III breast cancer were treated with NPLD (60 mg/m(2)) and docetaxel (75 mg/m(2)) on day 1 and gemcitabine as 4-h infusion (350 mg/m(2)) on day 4.
  • Patients with axillary lymph node involvement after primary chemotherapy received adjuvant treatment with cyclophosphamide, methotrexate and fluorouracil.
  • RESULTS: The clinical response rate was 80%, and complete remissions of the primary tumor occurred in 10 patients (25%).
  • Most common non-hematologic toxicities were nausea, vomiting, alopecia, mucositis, asthenia and elevation of liver enzymes.
  • CONCLUSION: The evaluated schedule provides a safe and highly effective combination treatment for patients with early breast cancer, which is suitable for phase III studies.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16030028.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Liposomes; 0 / Taxoids; 0W860991D6 / Deoxycytidine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 15H5577CQD / docetaxel; 80168379AG / Doxorubicin; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


86. Nedic O, Malenkovic V, Dukanovic B, Baricevic I: Association of elevated IGFBP-1 with increased IGF-II concentration in patients with carcinoma of the liver. Int J Biol Markers; 2008 Oct-Dec;23(4):225-30
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of elevated IGFBP-1 with increased IGF-II concentration in patients with carcinoma of the liver.
  • Insulin-like growth factors (IGFs) are mitogens for numerous types of cells including cancer cells.
  • The aim of this work was to analyze some of the components of the IGF system to assess which could be potential clinical biomarkers for monitoring patients diagnosed with liver cancer.
  • Compared to healthy persons, patients with liver cancer had a lower concentration of IGF-I and a higher concentration of IGFBP-1, whereas the concentrations of IGF-II and IGFBP-3 remained unchanged.
  • The IGF-I:IGFBP-3 ratio decreased in patients with cancer, while the IGF-II:IGFBP-1 ratio was not altered.
  • Patients with primary carcinoma and those scheduled for surgery had lower IGF-I and higher IGF-II and IGFBP-1 concentrations than patients with secondary carcinoma and those not eligible for surgery.
  • It may be postulated that a liver with primary cancer is induced to increase IGF-II and IGFBP-1 synthesis more than a liver involved in metastatic response.
  • Similarly, in patients eligible for liver surgery an increase in IGF-II may reflect a gradual change in the concentration associated with a different stage of disease.
  • As increased synthesis of certain IGFBPs is necessary to compensate decreased production of the others or increased IGF production, determination of serum IGF-II, IGFBP-1 and their ratio may aid in estimating the compensatory capacity of the liver affected by cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Insulin-Like Growth Factor Binding Protein 1 / metabolism. Insulin-Like Growth Factor I / metabolism. Insulin-Like Growth Factor II / metabolism. Liver Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Blood Glucose. Case-Control Studies. Female. Humans. Insulin / blood. Insulin-Like Growth Factor Binding Protein 3. Insulin-Like Growth Factor Binding Proteins / blood. Liver Cirrhosis / blood. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19199270.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Glucose; 0 / IGFBP3 protein, human; 0 / Insulin; 0 / Insulin-Like Growth Factor Binding Protein 1; 0 / Insulin-Like Growth Factor Binding Protein 3; 0 / Insulin-Like Growth Factor Binding Proteins; 67763-96-6 / Insulin-Like Growth Factor I; 67763-97-7 / Insulin-Like Growth Factor II
  •  go-up   go-down


87. Zhou L, Yang YP, Feng YY, Lu YY, Wang CP, Wang XZ, An LJ, Zhang X, Wang FS: Efficacy of argon-helium cryosurgical ablation on primary hepatocellular carcinoma: a pilot clinical study. Ai Zheng; 2009 Jan;28(1):45-8
Hazardous Substances Data Bank. HELIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of argon-helium cryosurgical ablation on primary hepatocellular carcinoma: a pilot clinical study.
  • BACKGROUND AND OBJECTIVE: Recent years, great progression has been made in treating primary hepatocellular carcinoma (HCC) with argon-helium cryosurgical ablation.
  • This study was to evaluate its efficacy on unresectable primary HCC.
  • METHODS: A total of 124 primary HCC patients were divided into early stage, middle stage and advanced stage groups according to BCLC staging classification.
  • The median survival time was 31.25 months in early stage group, 17.41 months in middle stage group and 6.82 months in advanced stage group.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Cryosurgery / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Argon. Female. Helium. Humans. Liver / physiopathology. Male. Middle Aged. Pilot Projects. Postoperative Complications / epidemiology. Survival Rate. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. Argon, Elemental .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19448416.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins; 206GF3GB41 / Helium; 67XQY1V3KH / Argon
  •  go-up   go-down


88. Abraham SC, Poterucha JJ, Rosen CB, Demetris AJ, Krasinskas AM: Histologic abnormalities are common in protocol liver allograft biopsies from patients with normal liver function tests. Am J Surg Pathol; 2008 Jul;32(7):965-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic abnormalities are common in protocol liver allograft biopsies from patients with normal liver function tests.
  • The utility of protocol liver allograft biopsies remains controversial, particularly in patients with normal liver function tests (LFTs).
  • However, histologic evaluation of these biopsies provides an opportunity to examine the types and severity of liver diseases that can occur in livers with normal clinical and biochemical function.
  • We studied 165 protocol allograft biopsies taken from 100 liver transplant patients at the time of normal LFTs and normal clinical function at 3 to 8 months (n=36), 1 year (n=52), 2 to 3 years (n=54), and 4 to 5 years (n=23).
  • Biopsies were classified as normal, minimal changes (eg, nonaggressive portal or lobular mononuclear inflammation, steatosis <10%), fatty liver disease, recurrent primary liver disease, and transplant-related disease (portal-based rejection or central venulitis, an inflammatory pattern that encompasses perivenular hepatocyte dropout, mononuclear inflammation, pigment-laden macrophages, and variable zone 3 fibrosis).
  • Forty-four (27%) showed histologic abnormalities that included fatty liver disease (n=19, nonalcoholic in 18 cases; 13 with mild steatosis, 6 with moderate steatosis, 7 with grade 1/3 steatohepatitic activity, and 2 with stage 1/4 steatohepatitic fibrosis), recurrent primary biliary cirrhosis (n=9; all stage 1/4), recurrent hepatitis C infection (n=6; grade 0/4 in 1, grade 1/4 in 5, stage 0/4 in 4, stage 1/4 in 1, and stage 2/4 in 1), recurrent sarcoidosis (n=1), Ito cell hyperplasia (n=4; marked in 2 and mild in 2), central venulitis (n=10; 5 with mild zone 3 fibrosis or central vein obliteration and 1 with central-portal bridging fibrosis), and mild acute portal rejection (n=2).
  • These most commonly include fatty liver disease, low-grade/low-stage recurrent hepatitis C and primary biliary cirrhosis, and central venulitis (including some cases with subsequent fibrosis progression).
  • The data support performance of protocol biopsies to assess allograft status, and provide insight into the types and severity of liver diseases that can smolder in transplanted (and by extension, probably also in native) livers with apparent normal function.
  • [MeSH-major] Liver Diseases / diagnosis. Liver Transplantation / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy. Child. Child, Preschool. Clinical Protocols. Fatty Liver / diagnosis. Fatty Liver / physiopathology. Female. Hepatitis C, Chronic / diagnosis. Hepatitis C, Chronic / physiopathology. Humans. Infant. Liver Cirrhosis, Biliary / diagnosis. Liver Cirrhosis, Biliary / physiopathology. Liver Function Tests. Male. Middle Aged. Transplantation, Homologous

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18460980.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Li Q, Wang J, Juzi JT, Sun Y, Zheng H, Cui Y, Li H, Hao X: Clonality analysis for multicentric origin and intrahepatic metastasis in recurrent and primary hepatocellular carcinoma. J Gastrointest Surg; 2008 Sep;12(9):1540-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonality analysis for multicentric origin and intrahepatic metastasis in recurrent and primary hepatocellular carcinoma.
  • METHODS: Histopathologic and genetic features of primary and recurrent tumors in 160 cases with HCC were analyzed.
  • By comparing the genetic information of loss of heterozygosity and microsatellite instability for 10 different markers between primary and recurrent tumor, 30.0% and 63.8% patients with recurrent HCC were considered to be MO and IM, respectively.
  • Analysis of stepwise regression identified that recurrence time, grading, portal vein invasion, tumor number, and Child's stage were the most important discriminating factors between MO and IM (p < 0.05).
  • Recurrence time, tumor grading, portal vein invasion, tumor number, and Child's stage are the most important discriminating factors between MO and IM.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Hepatitis B / epidemiology. Liver Neoplasms / genetics. Liver Neoplasms / pathology. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Age Distribution. Biopsy, Needle. China / epidemiology. Cohort Studies. Female. Humans. Immunohistochemistry. Incidence. Kaplan-Meier Estimate. Loss of Heterozygosity. Male. Microsatellite Repeats. Middle Aged. Multivariate Analysis. Neoplasm Staging. Polymerase Chain Reaction. Probability. Regression Analysis. Retrospective Studies. Risk Assessment. Sex Distribution. Survival Analysis

  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18629593.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


90. van der Pool AE, Lalmahomed ZS, de Wilt JH, Eggermont AM, Ijzermans JN, Verhoef C: Trends in treatment for synchronous colorectal liver metastases: differences in outcome before and after 2000. J Surg Oncol; 2010 Oct 1;102(5):413-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in treatment for synchronous colorectal liver metastases: differences in outcome before and after 2000.
  • BACKGROUND: The traditional treatment for stage IV colorectal cancer has changed from palliative chemotherapy toward an aggressive multimodality approach.
  • In the current study outcome in patients who underwent surgery for synchronous colorectal liver metastases (CLM) in a single center was evaluated.
  • METHODS: From January 1991 to May 2008 all consecutive patients with synchronous CLM who underwent curative resection of both primary and metastatic disease were included.
  • The introduction of new chemotherapeutic drugs and a more aggressive treatment approach in patients with liver recurrence were probably major factors in this progress.
  • [MeSH-major] Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] J. Surg. Oncol. 2010;102:413-418. © 2010 Wiley-Liss, Inc.
  • (PMID = 20544718.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Lee YC, Pan HW, Peng SY, Lai PL, Kuo WS, Ou YH, Hsu HC: Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma. Eur J Cancer; 2007 Mar;43(4):736-44
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma.
  • By RT-PCR in the linear range, TATI was found to be overexpressed in 176 of 258 unifocal primary HCCs (68%).
  • TATI overexpression correlated with high-stage HCC (stage IIIB to IV) with portal vein (PV) invasion (p=0.00014), early tumour recurrence (ETR; p=0.00002), and a lower 5-year survival (p=0.000001), in both low- and high-stage HCC (p=0.033 and p=0.00036, respectively).
  • Thus, it is a stage-independent prognostic factor for HCC and a useful predictor for ETR.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Neoplasm Proteins / metabolism. Portal Vein. Trypsin Inhibitor, Kazal Pancreatic / metabolism
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. HeLa Cells / metabolism. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Osteopontin / metabolism. Prognosis. Survival Analysis. alpha-Fetoproteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17267202.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / alpha-Fetoproteins; 106441-73-0 / Osteopontin; 50936-63-5 / Trypsin Inhibitor, Kazal Pancreatic
  •  go-up   go-down


92. Zhang L, Ren ZG, Gan YH, Wang YH, Zhang BH, Chen Y, Xie XY, Ge NL, Ye SL: [Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma]. Zhonghua Zhong Liu Za Zhi; 2010 Aug;32(8):630-3
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma].
  • OBJECTIVE: To evaluate the efficacy and analyze the prognostic factors of sorafenib treatment in patient with unresectable primary hepatocellular carcinoma (HCC).
  • METHODS: During the period from December 2005 to March 2009, 50 patients with unresectable primary HCC of Child-Pugh status A were treated with sorafenib (400 mg, Bid).
  • The common adverse events were dermal reaction (68.0%, 34/50), diarrhea (52.0%, 26/50), hypertension (4.0%, 2/50), hair loss (14.0%, 7/50), myelosuppression (16.0%, 8/50), and liver dysfunction (20.0%, 10/50).
  • CONCLUSION: Soafenib is effective for unresectable primary HCC with tolerable toxicity.
  • Tumor stage is a predominant prognostic factor.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Pyridines / therapeutic use
  • [MeSH-minor] Adult. Aged. Alopecia / chemically induced. Chemoembolization, Therapeutic / methods. Diarrhea / chemically induced. Disease Progression. Follow-Up Studies. Humans. Hypertension / chemically induced. Male. Middle Aged. Neoplasm Staging. Niacinamide / analogs & derivatives. Phenylurea Compounds. Skin Diseases / chemically induced. Survival Rate

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21122420.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


93. Stapley S, Peters TJ, Sharp D, Hamilton W: The mortality of colorectal cancer in relation to the initial symptom at presentation to primary care and to the duration of symptoms: a cohort study using medical records. Br J Cancer; 2006 Nov 20;95(10):1321-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The mortality of colorectal cancer in relation to the initial symptom at presentation to primary care and to the duration of symptoms: a cohort study using medical records.
  • The association between the staging of colorectal cancer and mortality is well known.
  • We performed a cohort study of 349 patients with primary colorectal cancer in whom all their prediagnostic symptoms and investigation results were known.
  • Survival data for 3-8 years after diagnosis were taken from the cancer registry.
  • Rectal bleeding as an initial symptom was associated with less advanced staging (odds ratio from one Duke's stage to the next 0.50, 95% confidence interval 0.31, 0.79; P=0.003) and with reduced mortality (Cox's proportional hazard ratio (HR) 0.56 (0.41, 0.79); P=0.001.
  • [MeSH-minor] Abdominal Pain / etiology. Adult. Aged. Aged, 80 and over. Case-Control Studies. Cohort Studies. Constipation / etiology. Diarrhea / etiology. Female. Gastrointestinal Hemorrhage / etiology. Humans. Male. Medical Records. Middle Aged. Neoplasm Staging. Occult Blood. Predictive Value of Tests. Weight Loss

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Aust N Z J Surg. 1991 Feb;61(2):137-40 [2001199.001]
  • [Cites] Eur J Surg Oncol. 1989 Oct;15(5):441-5 [2551743.001]
  • [Cites] Eur J Surg Oncol. 1999 Apr;25(2):173-8 [10218461.001]
  • [Cites] Am J Gastroenterol. 1999 Oct;94(10):3039-45 [10520866.001]
  • [Cites] Colorectal Dis. 2005 Mar;7(2):169-71 [15720357.001]
  • [Cites] Br J Cancer. 2005 Aug 22;93(4):399-405 [16106247.001]
  • [Cites] Fam Pract. 2006 Feb;23(1):15-9 [16286462.001]
  • [Cites] Colorectal Dis. 2006 Jun;8(5):423-9 [16684087.001]
  • [Cites] Colorectal Dis. 2006 Jul;8(6):518-21 [16784474.001]
  • [Cites] BMJ. 2006 Jul 8;333(7558):69-70 [16790459.001]
  • [Cites] Colorectal Dis. 2006 Oct;8(8):688-95 [16970580.001]
  • [Cites] BMJ. 2001 Jun 30;322(7302):1555-6 [11431280.001]
  • [Cites] Dig Liver Dis. 2000 May;32(4):312-7 [11515629.001]
  • [Cites] Postgrad Med J. 2002 Sep;78(923):533-7 [12357013.001]
  • [Cites] Ann R Coll Surg Engl. 2002 Nov;84(6):381-5 [12484575.001]
  • [Cites] Scand J Gastroenterol. 2004 Mar;39(3):252-8 [15074395.001]
  • [Cites] World J Surg. 2004 Jul;28(7):716-20 [15383871.001]
  • [Cites] Eur J Surg Oncol. 1986 Jun;12(2):127-30 [3709816.001]
  • [Cites] Eur J Cancer. 1997 Aug;33(9):1461-7 [9337690.001]
  • (PMID = 17060933.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2360591
  •  go-up   go-down


94. Krasinskas AM, Yao Y, Randhawa P, Dore MP, Sepulveda AR: Helicobacter pylori may play a contributory role in the pathogenesis of primary sclerosing cholangitis. Dig Dis Sci; 2007 Sep;52(9):2265-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helicobacter pylori may play a contributory role in the pathogenesis of primary sclerosing cholangitis.
  • Helicobacter pylori (H. pylori) DNA has been identified in human livers and has been implicated in chronic liver disease and liver cancer.
  • To better understand the role of H pylori in primary sclerosing cholangitis (PSC), 25 patients with end-stage PSC and 31 controls were studied.
  • Genomic DNA was extracted from microdissected hilar hepatic ducts of liver explants and was amplified for H pylori DNA.
  • [MeSH-minor] Adolescent. Adult. Aged. Bile Ducts, Intrahepatic / microbiology. Bile Ducts, Intrahepatic / pathology. Biopsy. Disease Progression. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunohistochemistry. Liver / microbiology. Liver / pathology. Male. Middle Aged. Polymerase Chain Reaction. Prognosis

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17393314.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / RNA, Bacterial
  •  go-up   go-down


95. Zhao M, Wang JP, Wu PH, Zhang FJ, Huang ZL, Li W, Zhang L, Pan CC, Li CX, Jiang Y: [Comparative analysis of TACE alone or plus RFA in the treatment of 167 cases of intermediate and advanced staged primary hepatocellular carcinoma]. Zhonghua Yi Xue Za Zhi; 2010 Nov 9;90(41):2916-21
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparative analysis of TACE alone or plus RFA in the treatment of 167 cases of intermediate and advanced staged primary hepatocellular carcinoma].
  • OBJECTIVE: To evaluate the clinical efficacy and survival rate of transarterial chemoembolization (TACE) alone or plus radiofrequency ablation (RFA) in patients with intermediate or advanced stage primary hepatocellular carcinoma (HCC).
  • In the TACE alone group, the median survival of intermediate stage HCC was 14 months, one-year survival rate 62.2%, three-year survival rate 13.3% and five-year survival rate 4.4%; In the TACE plus RFA group, the median survival of intermediate stage HCC was 14 months, one-year survival rate 90.1%, three-year survival rate 52.9% and five-year survival rate 13.7%.
  • In intermediate stage HCC, the median survival of TACE alone group was 14 months, one-year survival rate 62.2%, three-year survival rate 13.3%, five-year survival rate 4.4% versus 32 months, 90.1%, 52.9%, 13.7% in the TACE plus RFA group respectively.
  • For the advanced stage HCC, the median survival time was 12 months, one-year survival rate 35%, three-year survival rate 7.1% and five-year survival rate 0 in the TACE alone group versus 28 months, 62.1%, 24.1% and 6.9% in the TACE plus RFA group (P = 0.00).
  • CONCLUSION: The regimen of TACE plus RFA has the advantages of tumor control, liver function protection and survival extending in the treatment of HCC than TACE alone in intermediate or advanced stage HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Catheter Ablation. Embolization, Therapeutic. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21211397.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


96. Guo Q, Tang W, Inagaki Y, Midorikawa Y, Kokudo N, Sugawara Y, Nakata M, Konishi T, Nagawa H, Makuuchi M: Clinical significance of subcellular localization of KL-6 mucin in primary colorectal adenocarcinoma and metastatic tissues. World J Gastroenterol; 2006 Jan 7;12(1):54-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of subcellular localization of KL-6 mucin in primary colorectal adenocarcinoma and metastatic tissues.
  • AIM: To assess subcellular localization of KL-6 mucin and its clinicopathological significance in colorectal carcinoma as well as metastatic lymph node and liver tissues.
  • METHODS: Colorectal carcinoma tissues as well as metastatic lymph node and liver tissues were collected from 82 patients who underwent colorectomy or hepatectomy.
  • Statistical analysis between clinicopathological factors and subcellular localization of KL-6 mucin showed that KL-6 localization in the circumferential membrane and/or cytoplasm was significantly associated with the presence of venous invasion (P = 0.0003), lymphatic invasion (P<0.0001), lymph node metastasis (P<0.0001), liver metastasis (P = 0.058), and advanced histological stage (P<0.0001).
  • Positive staining was observed in all metastatic lesions tested as well as in the primary colorectal carcinoma tissues.
  • CONCLUSION: The subcellular staining pattern of KL-6 in colorectal adenocarcinoma may be an important indicator for unfavorable behaviors such as lymph node and liver metastasis, as well as for the prognosis of patients.
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Middle Aged. Mucin-1. Survival Rate

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1988 Mar 25;263(9):4215-22 [3346246.001]
  • [Cites] World J Gastroenterol. 2005 Sep 21;11(35):5450-4 [16222735.001]
  • [Cites] J Biol Chem. 1990 Sep 5;265(25):15286-93 [1697589.001]
  • [Cites] Int J Oncol. 2000 Mar;16(3):455-9 [10675475.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2000 Mar;278(3):L625-9 [10710536.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):1973-82 [11391575.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):466-71 [11914624.001]
  • [Cites] World J Gastroenterol. 2001 Jun;7(3):425-30 [11819805.001]
  • [Cites] Biochem Biophys Res Commun. 2002 May 17;293(4):1183-90 [12054500.001]
  • [Cites] Histopathology. 2003 Mar;42(3):239-45 [12605643.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):5011-20 [12941828.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):45-60 [14681689.001]
  • [Cites] World J Gastroenterol. 2004 Oct 15;10(20):3044-7 [15378790.001]
  • [Cites] Hybridoma. 1984 Fall;3(3):223-32 [6094338.001]
  • [Cites] J Biol Chem. 1990 Sep 5;265(25):15294-9 [2394722.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1113-23 [2045853.001]
  • [Cites] Cancer Res. 1992 Apr 15;52(8):2318-24 [1559234.001]
  • [Cites] Cancer Res. 1992 May 1;52(9):2563-8 [1373671.001]
  • [Cites] Cancer. 1993 Apr 1;71(7):2191-9 [8384065.001]
  • [Cites] Gastroenterology. 1994 Feb;106(2):353-61 [7905449.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Feb;78(2):337-42 [8106621.001]
  • [Cites] J Cell Biol. 1995 Apr;129(1):255-65 [7698991.001]
  • [Cites] Annu Rev Physiol. 1995;57:607-34 [7778880.001]
  • [Cites] J Surg Oncol. 1996 Jul;62(3):171-6 [8667623.001]
  • [Cites] Nat Med. 1998 Jan;4(1):43-9 [9427605.001]
  • [Cites] Oncology. 1998 Jul-Aug;55(4):307-19 [9663420.001]
  • [Cites] Dis Colon Rectum. 1998 Oct;41(10):1262-72 [9788390.001]
  • [Cites] Hepatogastroenterology. 2005 Jan-Feb;52(61):67-71 [15782996.001]
  • [Cites] Jpn J Clin Oncol. 1988 Sep;18(3):203-16 [3411786.001]
  • (PMID = 16440417.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens; 0 / Antigens, Neoplasm; 0 / Glycoproteins; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / Mucins
  • [Other-IDs] NLM/ PMC4077483
  •  go-up   go-down


97. Lim GH, Wong CS, Chow KY, Bhalla V, Chia KS: Trends in long-term cancer survival in Singapore: 1968-2002. Ann Acad Med Singapore; 2009 Feb;38(2):99-105
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in long-term cancer survival in Singapore: 1968-2002.
  • INTRODUCTION: The life expectancy of cancer patients has increased in recent decades due to better diagnostic and screening tools as well as better treatment modalities.
  • Hence, it becomes increasingly important to study trends in long-term cancer patient survival in order to document that medical progress has conveyed benefit at the population level.
  • In this paper, we assessed the long-term survival experience of all incident cancer patients in Singapore.
  • MATERIALS AND METHODS: The study population consisted of patients diagnosed with single primary invasive cancer from 1 January 1968 to 31 December 2002, and passively followed up to 31 December 2005.
  • The data was derived from the Singapore Cancer Registry, which has been in existence since 1968.
  • Sex- and stage-specific survival was compared for each cancer.
  • A steady improvement in overall long-term cancer survival was observed over the study period.
  • In contrast, survival of cancers with poor prognosis such as lung, liver and pancreas remained low.
  • CONCLUSIONS: Although factors such as changes in diagnostic criteria could influence the trend in survival, we believed that the improvement in survival predominantly reflected real progress in cancer control in Singapore.
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Male. Middle Aged. Prognosis. Retrospective Studies. Sex Distribution. Singapore / epidemiology. Survival Rate / trends. Time Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19271035.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


98. Song Y, Wang LH, He J, Wang JW: [Treatment and prognosis of primary esophageal small cell carcinoma: a report of 151 cases]. Ai Zheng; 2009 Mar;28(3):303-7
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment and prognosis of primary esophageal small cell carcinoma: a report of 151 cases].
  • BACKGROUND AND OBJECTIVE: The treatment and prognosis of primary esophageal small cell carcinoma (PESC), an uncommon esophageal malignant tumor, have seldom been reported.
  • METHODS: Clinical data of 151 patients treated in Cancer Hospital, Chinese Academy of Medical Sciences, from 1982 to 2007 were reviewed.
  • The clinical stage and vessel involvement were independent prognostic factors of PESC.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Neoplastic Cells, Circulating / pathology. Proportional Hazards Models. Radiotherapy, Adjuvant. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19619447.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


99. Chen MS, Zhang YJ, Li JQ, Liang HH, Zhang YQ, Lin XJ, Zheng Y, Xu L, Wan YL: [Experience of radiofrequency ablation on liver malignancies: a report of 803 cases]. Zhonghua Wai Ke Za Zhi; 2007 Nov 1;45(21):1469-71
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Experience of radiofrequency ablation on liver malignancies: a report of 803 cases].
  • OBJECTIVE: To summarize the 8-year experience of radiofrequency ablation (RFA) on liver malignancies and explore the effect and prognostic factors.
  • METHODS: From August 1999 to February 2007, 803 patients with liver malignancies, among which there were 672 with primary liver cancer (PLC) and 131 with liver metastasis, were treated with RFA.
  • RESULTS: In the treatment of all the 803 patients with liver malignancies, the mortality was 0.25%, the rate of severe complications was 0.37%.
  • For the 672 patients with PLCs, the 1, 2, 3, 4, 5-year survivals with stage Ia (Chinese staging system) were 97.8%, 91.5%, 84.6%, 77.1% and 61.9%, respectively, with stage Ib were 93.9%, 83.7%, 69.8%, 45.1% and 42.2%, respectively, with stage II were 86.2%, 67.3%, 47.3%, 17.2% and 0, respectively, and the 1, 2-year survivals with stage III were 67.8% and 0, respectively (P < 0.01).
  • CONCLUSIONS: RFA is a safe and effective method for liver malignancy, and the tumor size and stage are important prognostic factors.
  • [MeSH-major] Catheter Ablation. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18275711.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


100. Heimbach JK, Gores GJ, Haddock MG, Alberts SR, Pedersen R, Kremers W, Nyberg SL, Ishitani MB, Rosen CB: Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation; 2006 Dec 27;82(12):1703-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma.
  • BACKGROUND: Sixty-five patients with unresectable hilar cholangiocarcinoma (CCA) have undergone orthotopic liver transplantation (OLT) after neoadjuvant chemoradiotherapy per a clinical care protocol developed in 1993.
  • Predictors of recurrence were older age, pretransplant cancer antigen (CA) 19-9 >100 U/ml, prior cholecystectomy, mass on cross-sectional imaging, residual tumor in explant >2 cm, tumor grade and perineural invasion in explant.
  • Underlying primary sclerosing cholangitis, percutaneous biliary intubation, gender, and other time points for CA 19-9 were not associated with recurrence.
  • Prolonged staging-to-OLT intervals for patients transplanted after implementation of model for end-stage liver disease (MELD) showed a trend toward increased recurrence.
  • [MeSH-major] Bile Duct Neoplasms / therapy. Bile Ducts, Intrahepatic. CA-19-9 Antigen / blood. Cholangiocarcinoma / therapy. Liver Transplantation. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Age Factors. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Prognosis. Risk Factors






Advertisement